US20100028260A1 - Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods - Google Patents
Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods Download PDFInfo
- Publication number
- US20100028260A1 US20100028260A1 US12/467,229 US46722909A US2010028260A1 US 20100028260 A1 US20100028260 A1 US 20100028260A1 US 46722909 A US46722909 A US 46722909A US 2010028260 A1 US2010028260 A1 US 2010028260A1
- Authority
- US
- United States
- Prior art keywords
- och
- poly
- color
- calibrated
- acrylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002245 particle Substances 0.000 title claims abstract description 152
- 238000000034 method Methods 0.000 title claims abstract description 32
- 230000001225 therapeutic effect Effects 0.000 title abstract description 11
- 239000000017 hydrogel Substances 0.000 claims abstract description 57
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 42
- 229920002627 poly(phosphazenes) Polymers 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- -1 poly(methacrylic acid) Polymers 0.000 claims description 93
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Chemical group 0.000 claims description 11
- 229910052698 phosphorus Inorganic materials 0.000 claims description 11
- 239000011574 phosphorus Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 239000011593 sulfur Chemical group 0.000 claims description 11
- 239000002872 contrast media Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 239000008177 pharmaceutical agent Substances 0.000 claims description 6
- 229920002319 Poly(methyl acrylate) Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 5
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 5
- 230000010102 embolization Effects 0.000 claims description 4
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 239000012867 bioactive agent Substances 0.000 claims description 3
- 125000004996 haloaryloxy group Chemical group 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 229920001485 poly(butyl acrylate) polymer Polymers 0.000 claims description 3
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 claims description 3
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 3
- 229920000120 polyethyl acrylate Polymers 0.000 claims description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 2
- 230000002421 anti-septic effect Effects 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- 125000005000 thioaryl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 21
- 238000010348 incorporation Methods 0.000 abstract description 20
- 230000003073 embolic effect Effects 0.000 abstract description 11
- 230000002500 effect on skin Effects 0.000 abstract description 9
- 239000000945 filler Substances 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 230000001404 mediated effect Effects 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract description 4
- 230000000007 visual effect Effects 0.000 abstract description 4
- 238000001514 detection method Methods 0.000 abstract description 3
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 239000000975 dye Substances 0.000 description 24
- 239000000985 reactive dye Substances 0.000 description 23
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 17
- 239000002504 physiological saline solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 0 [1*]C1=NC([2*])=NC(Cl)=N1 Chemical compound [1*]C1=NC([2*])=NC(Cl)=N1 0.000 description 12
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- KUIXZSYWBHSYCN-UHFFFAOYSA-L remazol brilliant blue r Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=C2C(=O)C3=CC=CC=C3C(=O)C2=C1NC1=CC=CC(S(=O)(=O)CCOS([O-])(=O)=O)=C1 KUIXZSYWBHSYCN-UHFFFAOYSA-L 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- BLFZMXOCPASACY-UHFFFAOYSA-N 1,4-bis(propan-2-ylamino)anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(NC(C)C)=CC=C2NC(C)C BLFZMXOCPASACY-UHFFFAOYSA-N 0.000 description 8
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 8
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- PGXGNDUJVQMEOW-UHFFFAOYSA-N nitro(nitroso)phosphane Chemical compound [O-][N+](=O)PN=O PGXGNDUJVQMEOW-UHFFFAOYSA-N 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 7
- WXQMFIJLJLLQIS-UHFFFAOYSA-N reactive blue 21 Chemical compound [Cu+2].C1=CC(S(=O)(=O)CCO)=CC=C1NS(=O)(=O)C1=CC=C2C([N-]3)=NC(C=4C5=CC=C(C=4)S(O)(=O)=O)=NC5=NC(C=4C5=CC=C(C=4)S(O)(=O)=O)=NC5=NC([N-]4)=C(C=C(C=C5)S(O)(=O)=O)C5=C4N=C3C2=C1 WXQMFIJLJLLQIS-UHFFFAOYSA-N 0.000 description 7
- 229910052711 selenium Inorganic materials 0.000 description 7
- 239000011669 selenium Substances 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- HWSSEYVMGDIFMH-UHFFFAOYSA-N 2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOC(=O)C(C)=C HWSSEYVMGDIFMH-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- HFIYIRIMGZMCPC-YOLJWEMLSA-J remazole black-GR Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC2=CC(S([O-])(=O)=O)=C(\N=N\C=3C=CC(=CC=3)S(=O)(=O)CCOS([O-])(=O)=O)C(O)=C2C(N)=C1\N=N\C1=CC=C(S(=O)(=O)CCOS([O-])(=O)=O)C=C1 HFIYIRIMGZMCPC-YOLJWEMLSA-J 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 5
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 241000894007 species Species 0.000 description 5
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical class ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 4
- INOIOAWTVPHTCJ-UHFFFAOYSA-N 6-acetamido-4-hydroxy-3-[[4-(2-sulfooxyethylsulfonyl)phenyl]diazenyl]naphthalene-2-sulfonic acid Chemical compound CC(=O)NC1=CC=C2C=C(C(N=NC3=CC=C(C=C3)S(=O)(=O)CCOS(O)(=O)=O)=C(O)C2=C1)S(O)(=O)=O INOIOAWTVPHTCJ-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 238000007334 copolymerization reaction Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 4
- 238000013152 interventional procedure Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- QRWVOJLTHSRPOA-UHFFFAOYSA-N 1,3-bis(prop-2-enyl)urea Chemical compound C=CCNC(=O)NCC=C QRWVOJLTHSRPOA-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003302 alkenyloxy group Chemical group 0.000 description 3
- 125000006193 alkinyl group Chemical group 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 125000005133 alkynyloxy group Chemical group 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- FBCQUCJYYPMKRO-UHFFFAOYSA-N prop-2-enyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC=C FBCQUCJYYPMKRO-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N 1-Pyrroline Chemical compound C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 2
- 206010003226 Arteriovenous fistula Diseases 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 230000005744 arteriovenous malformation Effects 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012206 bottled water Nutrition 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000008358 core component Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010557 suspension polymerization reaction Methods 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 2
- 239000010981 turquoise Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- UPNNXUSUOSTIIM-UHFFFAOYSA-N 1,2-dithietane Chemical compound C1CSS1 UPNNXUSUOSTIIM-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- RTLULCVBFCRQKI-UHFFFAOYSA-N 1-amino-4-[3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=1)=CC=C(S(O)(=O)=O)C=1NC1=NC(Cl)=NC(Cl)=N1 RTLULCVBFCRQKI-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- SPSSDDOTEZKOOV-UHFFFAOYSA-N 2,3-dichloroquinoxaline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=NC2=C1 SPSSDDOTEZKOOV-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- YPIPEOPDBFEXKV-UHFFFAOYSA-N 4-chloro-5-fluorotriazine Chemical class FC1=CN=NN=C1Cl YPIPEOPDBFEXKV-UHFFFAOYSA-N 0.000 description 1
- ORLGPUVJERIKLW-UHFFFAOYSA-N 5-chlorotriazine Chemical class ClC1=CN=NN=C1 ORLGPUVJERIKLW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- CEZCCHQBSQPRMU-LLIZZRELSA-L Allura red AC Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1\N=N\C1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-LLIZZRELSA-L 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- ODENJAUDXHRKCL-UHFFFAOYSA-N C1CCSC1.C1CCSC1.C1CC=CS1 Chemical compound C1CCSC1.C1CCSC1.C1CC=CS1 ODENJAUDXHRKCL-UHFFFAOYSA-N 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- AEKNYBWUEYNWMJ-QWOOXDRHSA-N Pramiconazole Chemical compound O=C1N(C(C)C)CCN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(CO3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 AEKNYBWUEYNWMJ-QWOOXDRHSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SYKNUAWMBRIEKB-UHFFFAOYSA-N [Cl].[Br] Chemical compound [Cl].[Br] SYKNUAWMBRIEKB-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 235000012741 allura red AC Nutrition 0.000 description 1
- 239000004191 allura red AC Substances 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000005290 antiferromagnetic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229910052798 chalcogen Inorganic materials 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 238000013161 embolization procedure Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N indirubin Chemical compound N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960004108 iobitridol Drugs 0.000 description 1
- YLPBXIKWXNRACS-UHFFFAOYSA-N iobitridol Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960000780 iomeprol Drugs 0.000 description 1
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960000824 iopentol Drugs 0.000 description 1
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- DDFOUSQFMYRUQK-RCDICMHDSA-N isavuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC=C(F)C=2)F)=NC=1C1=CC=C(C#N)C=C1 DDFOUSQFMYRUQK-RCDICMHDSA-N 0.000 description 1
- 229960000788 isavuconazole Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052696 pnictogen Inorganic materials 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229950001086 pramiconazole Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 150000003553 thiiranes Chemical class 0.000 description 1
- 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0404—X-ray contrast preparations containing barium sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
Definitions
- This disclosure relates to various polymeric particles incorporating chromophores and other agents of interest that can be employed as implantable devices in animal subjects, for various diagnostic and therapeutic applications.
- various cosmetic, clinical, and interventional procedures involve in vivo administration of synthetic particles, manufactured in various sizes and compositions.
- various blends of polymeric embolic particles can be introduced into the lumen of blood vessels to intentionally impede blood flow through various tissues/organs affected with physical trauma, tumor, or any condition in which blood-flow intervention can provide an effective and noninvasive form of temporary or permanent mode of therapy (“embolization”).
- the manufactured products containing such synthetic particles require further manipulation by the practitioner prior to in vivo administration.
- the particle-based products provided by a manufacturer need to be combined with other reagents in order to make a final sample preparation suitable for in vivo administration.
- Substantial human errors can be inadvertently introduced during the preparatory procedures that may increase the overall risk associated with performing a given treatment.
- Practitioners need particles formulated to minimize various types of risks introduced during sample preparations for various particle-mediated diagnostic and/or therapeutic applications.
- color-coded and size-calibrated polymeric particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising polyphosphazenes of formula I, useful for various therapeutic and/or diagnostic procedures.
- the color-coded and size-calibrated polymeric particles can be employed in any particle-mediated procedure, including as embolic agents, dermal fillers, and various implantable devices for a broad range of clinical and cosmetic applications.
- FIG. 1 is a schematic of an exemplary color-coded and size-calibrated polymeric particle comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising a polyphosphazene coating of formula I.
- FIG. 2 is an exemplary reaction scheme for the incorporation of reactive dye molecules by forming activated groups within reactive dye molecules before reacting with acrylate-based hydrogels in the presence of a coupling agent.
- FIG. 3 is an exemplary reaction scheme for the incorporation of reactive dye molecules by forming activated groups within acrylate-based hydrogels before reacting with reactive dye molecules.
- FIG. 4 is a schematic of an interventional occlusion of a hypothetical blood vessel employing particles of at least three different diameter sizes, each set of particles labeled according to a different color scheme.
- particle-mediated procedure refers to any procedure that involves the utilization of disclosed particles in order to facilitate a diagnostic purpose and/or a therapeutic purpose.
- Exemplary particle-mediated procedures include various intravascular interventional procedures (“embolization”) involving in vivo administration of synthetically made particles of various compositions for reducing or stopping blood flow into the affected tissue/organ, including: for controlling gastrointestinal bleeding of any cause, for controlling bleeding into the abdomen or pelvis from any physical trauma injuries, for controlling bleeding resulting from long menstrual periods or heavy menstrual bleeding caused by uterine fibroid tumors, for occluding vessels that are supplying blood to tumors, for eliminating arteriovenous malformation (AVM) or arteriovenous fistula (AVF) caused by abnormal connection or connections between arteries and veins, for treating various types of aneurysms, and various other conditions and diseases suitable for such particle-mediated interventional procedures.
- AMM arteriovenous malformation
- AVF arteriovenous fistula
- the contemplated “particle-mediated procedures” include any procedure in which a benefit can be conferred by the targeted delivery of particles of interest for any form of therapy, including various diagnostic, therapeutic, and cosmetic applications.
- the particles can be delivered to any tissue or organ of a recipient.
- the type of optimal particles (size range, color, composition) suitable for a given condition under contemplation would need to be determined by the practitioner.
- particle(s),” “color-coded particles,” and “color-coded and size-calibrated particles” can be used interchangeably to refer to any synthetically made particle of any shape or surface contour, with an average diameter size ranging from approximately 10 ⁇ m to approximately 1500 ⁇ m, that can be employed for any particle-based procedure, and includes various embolic particles and dermal-filler particles.
- the particles refer to substantially polymeric bodies shaped or formed as substantially spherical or ellipsoid articles manufactured to a particular size or diameter of interest and incorporating one or more chromophores of interest in order to produce a set of particles characterized by a particular predetermined size and color.
- embolic particles refers to any synthetically made particle of any shape or surface contour, with an average diameter size ranging from approximately 10 ⁇ m to approximately 1500 ⁇ m, suitable for any embolization procedure, and exemplifies “color-coded and size-calibrated particles.”
- each set of particles calibrated for a particular size/dimension can be manufactured to incorporate a particular color desired to match the size-calibrated particles so that each set of such particles can be visually identified by the particular color exhibited (“color-coded”).
- Suitable embolic particles can be composed of any material amendable to controlled manufacturing and production specifications according to shaping and sizing requirements.
- Embolic particles are typically suspended in a transport medium containing various components that stabilize the particles during storage and shipment by manufacturers.
- the color-coded and size-calibrated particles can be employed as embolic agents for treating hypertrophic obstructive cardiomyopathy (HCM), having an average diameter size ranging from approximately 50 ⁇ m to approximately 90 ⁇ m, preferably from approximately 60 ⁇ m to approximately 80 ⁇ m, and most preferably from approximately 70 ⁇ m to approximately 75 ⁇ m.
- HCM hypertrophic obstructive cardiomyopathy
- skin-filler particles refers to any synthetically made particle of any shape or surface contour, with an average diameter size ranging from approximately 50 ⁇ m to approximately 500 ⁇ m, from approximately 50 ⁇ m to approximately 400 ⁇ m, from approximately 50 ⁇ m to approximately 300 ⁇ m, from approximately 50 ⁇ m to approximately 200 ⁇ m, suitable for any cosmetic application procedure, and exemplifies “color-coded and size-calibrated particles.”
- Suitable dermal-filler particles can be composed of any material amendable to controlled manufacturing and production specifications according to shaping and sizing requirements.
- Dermal-filler particles can be administered to a recipient in need of cosmetic and/or therapeutic enhancement in appearance, including the removal of wrinkles, dermal texture imperfections, dermal blot clots, dermal age-related disease or damage, and other equivalent conditions known by persons skilled in the art of dermal cosmetic enhancement and dermal diagnostic/clinical/therapeutic applications.
- Mixtures of chromophores formulated to resemble various skin tones can be incorporated into the acrylate-based hydrogel cores of color-coded and size-calibrated particles manufactured for use as dermal fillers.
- acrylate-based hydrogel refers to any polymer chain, formed in part or entirely, through the polymerization of an acrylate based monomer and (optionally) through subsequent and/or parallel reactions, can be three-dimensionally crosslinked, and having pendant side groups to confer the resulting cross-linked polymeric network with a substantial affinity for particular solvents, such as water, and to enable swelling.
- gel refers to an elastic colloid or polymeric network capable of expanding throughout the volume by the absorption of fluid.
- the polymer network can be a network formed by covalent bonds or by physical aggregation with region of local order acting as network junctions. Both by weight and volume, gels can be mostly liquid in composition and thus exhibit densities similar to that of liquids, however, gels have the structural coherence of a solid.
- hydrogel refers to a polymeric network capable of absorbing water.
- crosslink refers to a small region in a macromolecule from which at least three chains emanate, and formed by reactions involving sites or groups on existing macromolecules or by interactions between existing macromolecules.
- the small region may be an atom, a group of atoms, or a number of branch points connected by bonds, groups of atoms, or oligomeric chains.
- a crosslink is a covalent structure but the term can describe sites of weaker chemical interactions, portions of crystallites, and even physical entanglements.
- chromophores refers to any molecule that can absorb certain wavelengths of visible light, and can transmit or reflect other wavelengths as understood by persons skilled in the art, and includes various nontoxic pigments and dyes of medical grade that can be incorporated into food and/or medical devices for implantation into human and/or animal subjects without imposing the risk of substantial harm
- the chromophores suitable for incorporation into particles of interest include dyes that have been approved or have been exempt from certification by the FDA, which are listed under TITLE 21—FOOD AND DRUGS, CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SUBCHAPTER A, GENERAL, PART 73 LISTING OF COLOR ADDITIVES EXEMPT FROM CERTIFICATION, Subpart D—Medical Devices, the disclosure of which is incorporated herein by reference.
- incorpora refers to any process involving the physical or chemical affixation of one or more species, including atoms, molecular entities, agents such as dyes, oligo- and polymeric species together.
- the term refers to processes involving impregnation, precipitation, covalent binding, grafting in- or onto, fixing in- or onto, diffusion, permeation, temporary or permanent, partial or complete localization within, around, throughout a given article.
- the color-coded and size-calibrated polymeric particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising polyphosphazenes of formula I, useful for various therapeutic and/or diagnostic procedures are provided.
- the color-coded and size-calibrated polymeric particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest and an outer shell comprising polyphosphazenes of formula I, can be employed as embolic particles for mediating various interventional procedures.
- the color-coded and size-calibrated polymeric particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest and an outer shell comprising polyphosphazenes of formula I, can be employed as embolic agents for treating hypertrophic obstructive cardiomyopathy (HCM).
- HCM hypertrophic obstructive cardiomyopathy
- the color-coded and size-calibrated polymeric particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest and an outer shell comprising polyphosphazenes of formula I, can be employed as dermal fillers.
- the biocompatible and loadable polymeric particles comprises an acrylate-based hydrogel core incorporating one or more chromophores of interest and an outer shell comprising poly[bis(trifluoroethoxy) phosphazene] and/or a derivative thereof.
- a particular chromophore formulation that correlates with a predetermined size range of implantable and loadable polymeric particles of interest (“color-coded” particles) permit a convenient and accurate visual identification of particles of interest and minimizes user-introduced errors.
- FIG. 1 is a schematic of an exemplary color-coded and size-calibrated polymeric particle comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising a polyphosphazene coating of formula I.
- a hypothetical particle 100 comprising an acrylate-based hydrogel core 110 and an outer shell 120 is shown.
- the acrylate-based hydrogel core 110 can be manufactured to incorporate various chromophores present in a sufficient amount to permit the detection of a “color” by a human eye or by an instrument.
- the total amount of chromophores sufficient to be visually detected can vary depending on particular chromophores selected.
- the total amount of chromophores that can be incorporated into the color-coded and size-calibrated particles can range up to about 20%, about 15%, about 10%, about 8%, about 6%, about 5%, or about 2.5% of the total dry weight of the hydrogel.
- An outer shell 120 comprising at least one polyphosphazene of formula I, can be formed on the surface of the acrylate-based hydrogel core 110 to provide a biocompatible coating layer.
- the color-coded and size-calibrated polymeric particles can be manufactured to be substantially uniform in size.
- the smallest average diameter of a set of particles for a first product line can be about 10 ⁇ m
- the largest average diameter of a set of particles for a second product line can be about 1500 ⁇ m.
- the average diameter size range of particles of interest can be selected from about 10 ⁇ m to about 1500 ⁇ m; from about 10 ⁇ m to about 1100 ⁇ m; from about 10 ⁇ m to about 1000 ⁇ m; from about 10 ⁇ m to about 900 ⁇ m; from about 10 ⁇ m to about 800 ⁇ m; from about 10 ⁇ m to about 700 ⁇ m; from about 10 ⁇ m to about 600 ⁇ m; from about 10 ⁇ m to about 500 ⁇ m; from about 10 ⁇ m to about 400 ⁇ m; from about 10 ⁇ m to about 300 ⁇ m; from about 10 ⁇ m to about 200 ⁇ m; from about 10 ⁇ m to about 175 ⁇ m; from about 10 ⁇ m to about 150 ⁇ m; from about 10 ⁇ m to about 120 ⁇ m; from about 10 ⁇ m to about 80 ⁇ m; and from about 10 ⁇ m to about 40 ⁇ m.
- Suitable range in average diameter size of a particle of interest include: from about 20 ⁇ m to about 1500 ⁇ m; from about 20 ⁇ m to about 1200 ⁇ m; from about 20 ⁇ m to about 1000 ⁇ m; from about 20 ⁇ m to about 900 ⁇ m; from about 20 ⁇ m to about 800 ⁇ m; from about 20 ⁇ m to about 700 ⁇ m; from about 20 ⁇ m to about 600 ⁇ m; from about 20 ⁇ m to about 500 ⁇ m; from about 20 ⁇ m to about 400 ⁇ m; from about 20 ⁇ m to about 300 ⁇ m; from about 20 ⁇ m to about 200 ⁇ m; from about 20 ⁇ m to about 175 ⁇ m; from about 20 ⁇ m to about 150 ⁇ m; from about 20 ⁇ m to about 120 ⁇ m; from about 20 ⁇ m to about 80 ⁇ m; and from about 20 ⁇ m to about 40 ⁇ m.
- Suitable range in average diameter size of a particle of interest include: from about 30 ⁇ m to about 1500 ⁇ m; from about 30 ⁇ m to about 1300 ⁇ m; from about 30 ⁇ m to about 3000 ⁇ m; from about 30 ⁇ m to about 900 ⁇ m; from about 30 ⁇ m to about 800 ⁇ m; from about 30 ⁇ m to about 700 ⁇ m; from about 30 ⁇ m to about 600 ⁇ m; from about 30 ⁇ m to about 500 ⁇ m; from about 30 ⁇ m to about 400 ⁇ m; from about 30 ⁇ m to about 300 ⁇ m; from about 30 ⁇ m to about 300 ⁇ m; from about 30 ⁇ m to about 175 ⁇ m; from about 30 ⁇ m to about 150 ⁇ m; from about 30 ⁇ m to about 130 ⁇ m; from about 30 ⁇ m to about 80 ⁇ m; and from about 30 ⁇ m to about 40 ⁇ m.
- the color-coded and size-calibrated polymeric particles can be calibrated to a predetermined deviation tolerance of less than or equal to about ⁇ 5%, less than or equal to about ⁇ 10%, less than or equal to about ⁇ 15%, less than or equal to about ⁇ 20%, less than or equal to about ⁇ 25%, less than or equal to about ⁇ 30%, or less than or equal to about ⁇ 35% from the design specification.
- the color-coded and size-calibrated polymeric particles can be manufactured to exhibit a narrow size distribution proportional to the average size of the particles.
- the particles within the range from about 700 ⁇ m to about 1000 ⁇ m can vary less than or equal to only about ⁇ 3-5% from the design specification, whereas particles within the size range from about 40 ⁇ m to about 100 ⁇ m can vary less than or equal to about ⁇ 20-25% from the design specification.
- the color-coded and size-calibrated polymeric particles can be manufactured to exhibit uniformity in shape, and preferably, the particles can be manufactured to be substantially spherical in shape.
- the color-coded and size-calibrated polymeric particles comprise an acrylate-based hydrogel, as a core component, that can be manufactured utilizing various polymers known to persons skilled in the art, including polymers selected from poly(methacrylic acid), poly(methyl acrylate), poly(methyl methacrylate) (PMMA), poly(ethyl methacrylate), poly(hexamethyl methacrylate), poly(hydroxyethyl methacrylate), poly(acrylic acid), poly(butyl acrylate), poly(2-ethylhexyl acrylate), poly(ethyl acrylate), poly(acrylonitrile), poly(trimethylolpropane triacrylate), or an equivalent known by persons skilled in the art, a copolymer thereof, and/or a combination thereof.
- FIG. 2 is an exemplary reaction scheme for the incorporation of reactive dye molecules by forming activated groups within reactive dye molecules before reacting with acrylate-based hydrogels in the presence of a coupling agent.
- a suitable reactive dye 200 can be amino-activated with an aliphatic diamine (ethylene diamine) 210 to form an aliphatic amino group within the reactive dye 220 , which can be reacted with a hypothetical acrylate-based hydrogel 230 in the presence of a coupling promoter agent 240 , such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), to produce color-coded and size-calibrated particles 250 incorporated with reactive dye molecules by a stable covalent linkage.
- a coupling promoter agent 240 such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
- Exemplary reactive dyes used in production FDA exempt from certification: Reactive Red 11 (dichlorotriazine), Reactive Yellow 86 (dichlorotriazine), Reactive Blue 4 (dichlorotriazine), Reactive Black 5 (vinyl sulfone), Reactive Red 180 (vinyl sulfone), Reactive Yellow 15 (vinyl sulfone), Reactive Blue 19 (vinyl sulfone), Reactive Blue 21 (vinyl sulfone), Reactive Blue 163 (vinyl sulfone), Reactive Orange 78 (vinyl sulfone), and others known to persons skilled in the art.
- These examples can be accordingly reformulated by replacing the nucleophilic group H 2 N— with —OH, —SH or any other arbitrary nucleophilic group.
- An exemplary formula for an amino activator spacer molecule is provided by: H 2 N—CH 2 —R—CH 2 —NH 2 , wherein the R is an alkylene, alkoxylene, alkenylene, alkinylene, arylene, and alkylarylene; includes carrying organic and heteroorganic side groups (such as hydroxyl, silyl, thiol, sulfonyl, sulfoxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate).
- organic and heteroorganic side groups such as hydroxyl, silyl, thiol, sulfonyl, sulfoxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate.
- FIG. 3 is an exemplary reaction scheme for the incorporation of reactive dye molecules by forming activated groups within acrylate-based hydrogels before reacting with reactive dye molecules.
- the carboxylic acid groups of the PMAA 300 as an hypothetical acrylate-based hydrogel, can be amino-activated by reacting with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 310 in the presence of an aliphatic diamine (ethylene diamine) 320 .
- EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
- the resulting free amino group within the activated acrylate-based hydrogel 330 can react with the reactive dyes 340 to produce the color-coded and size-calibrated particles 350 incorporated with reactive dye molecules by a stable covalent linkage.
- active anchor groups can be created within the PMAA core of color-coded and size-calibrated particles during the polymerization process of PMMA.
- co-polymerization of MMA in the presence of a small amount (about 1-10%) of amino (—NH 2 ) or hydroxyl (—OH) groups (or protected forms of both) containing unsaturated species can generate active anchor groups so that reactive dyes can be directly bound to the hydrogel core without prior activation without requiring ethylene diamine via EDC to activate the hydrogel core or amino activation of dye molecules.
- exemplary co-polymers include unsaturated alcohols, unsaturated amines, and unsaturated thiols.
- the generalized formula for unsaturated alcohols is R 5 O—R 1 —CR 2 ⁇ CR 3 R 4
- R 1 is any bivalent group with no electron withdrawing impact on —OH; this includes but is not limited to alkylene, alkoxylene, alkenylene, alkinylene, arylene, and alkylarylene, also including organic and heteroorganic side groups (e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate);
- organic and heteroorganic side groups e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate
- R 2 , R 3 and/or R 4 enable copolymerization and include but are not limited to hydrogen, halogen, alkyl, alkoxyl, alkenyl, alkinyl, aryl, and alkylaryl, or any combinations or derivatives thereof, also including any organic and heteroorganic side groups (e.g. silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate); and
- R 5 includes hydrogen or any protecting group.
- the generalized formula for unsaturated amine is: R 5 HN—R 1 —CR 2 ⁇ CR 3 R 4
- R 1 is any bivalent group with no electron withdrawing impact on —OH; this includes but is not limited to alkylene, alkoxylene, alkenylene, alkinylene, arylene, and alkylarylene, also including organic and heteroorganic side groups (e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate);
- organic and heteroorganic side groups e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate
- R 2 , R 3 and/or R 4 enable copolymerization and include but are not limited to hydrogen, halogen, alkyl, alkoxyl, alkenyl, alkinyl, aryl, and alkylaryl, or any combinations or derivatives thereof, also including any organic and heteroorganic side groups (e.g. silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate); and
- R 5 includes hydrogen or any protecting group.
- Exemplary unsaturated amines include vinyl amine (H 2 C ⁇ CH—NH 2 ) or derivatives [H 2 C ⁇ CH—(CH 2 ) n —NH 2 ] (n ⁇ 1).
- R 1 is any bivalent group with no electron withdrawing impact on —OH; this includes but is not limited to alkylene, alkoxylene, alkenylene, alkinylene, arylene, and alkylarylene, also including organic and heteroorganic side groups (e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate);
- organic and heteroorganic side groups e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate
- R 2 , R 3 and/or R 4 enable copolymerization and include but are not limited to hydrogen, halogen, alkyl, alkoxyl, alkenyl, alkinyl, aryl, and alkylaryl, or any combinations or derivatives thereof, also including any organic and heteroorganic side groups (e.g. silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate); and
- R 5 includes hydrogen or any protecting group.
- the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate any compound/agent of interest suitable for various therapeutic and/or diagnostic applications.
- the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate any bioactive and pharmaceutical agents, such as peptides, proteins, hormones, carbohydrates, polysaccharides, nucleic acids, lipids, vitamins, steroids, organic or inorganic drugs, and/or equivalents, and combinations thereof.
- bioactive and pharmaceutical agents such as peptides, proteins, hormones, carbohydrates, polysaccharides, nucleic acids, lipids, vitamins, steroids, organic or inorganic drugs, and/or equivalents, and combinations thereof.
- the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate various fluorescent dyes, radiopaque reagents, and/or equivalents to permit contemporaneous monitoring, and combinations thereof.
- the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate magnetic, diamagnetic, paramagnetic, ferromagnetic and/or antiferromagnetic elements to impart certain magnetic properties.
- the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate various excipients, such as dextranes, other sugars, polyethylene glycol, glucose, and various salts.
- excipients such as dextranes, other sugars, polyethylene glycol, glucose, and various salts.
- contrast agent refers to various compounds, suspended in contrast medium/media, that enables radiopaque visibility by highlighting specific tissue/organ of interest during various diagnostic medical imaging examinations and/or treatment procedures that require simultaneous monitoring, by various means including: x-ray exams, computed tomography scans, and magnetic resonance imaging.
- contrast agents include iobitridol, iodixanol, iomeprol, iopamidol, iopentol, iopromide, ioversol, and other iodine-formulated compositions, which have iodine concentrations between about 240 mg/ml to about 400 mg/ml, or more.
- a larger volume of contrast medium may be required to sufficiently saturate the particles with an iodine threshold level necessary to provide adequate radiopaque visibility when monitoring particle transport following in vivo administration.
- the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate barium sulfate, which can be utilized for increasing the density of the particle, so that the particle can be properly suspended within a dense medium, such as a contrast agent-containing solution, for modulating or enhancing the added chromophore by creating varying degrees of translucency, contributing to the intensity of the color perceived, for changing the elastic and mechanic properties of a particle as an inelastic component, and/or for increasing the radiopaqueness of a particle, without the use of separate contrast agent, capable of acting as a contrast agent in itself.
- barium sulfate which can be utilized for increasing the density of the particle, so that the particle can be properly suspended within a dense medium, such as a contrast agent-containing solution, for modulating or enhancing the added chromophore by creating varying degrees of translucency, contributing to the intensity of the color perceived, for changing the elastic and mechanic properties of a particle as an inelastic component, and/
- Various embodiments are directed to color-coded and size-calibrated particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising polyphosphazenes having the general formula (I):
- Suitable substituents for R 1 to R 6 can be independently selected from the group consisting of: halide substituents, such as fluorine, chlorine bromine, or iodine; pseudohalide substituents, such as cyano (—CN), isocyano (—NC), thiocyano (—SCN), isothiocyano (—NCS), cyanato (—OCN), isocyanato (—NCO), or azido (—N 3 ) groups; substituents such as nitro- (—NO 2 ) or nitrito (—NO) groups; partially substituted alkyl groups, such as haloalkyl; heteroaryl such as imidazoyl, oxazolyl, thiazolyl, or pyrazolyl derivatives; and purine and pyrimidine bases such as guanidines, amidines or other ureido derivatives of the base structure.
- halide substituents such as fluorine, chlorine bromine, or iod
- R can be selected independently from a linear, branched, and/or cyclic (“cycloalkyl”) hydrocarbyl moieties, including alkyl (saturated hydrocarbons) as well as alkenyl and alkynyl moieties, having from 1 to about 20 (for example, from 1 to about 12, or 1 to about 6) carbon atoms.
- cycloalkyl cyclic hydrocarbyl moieties, including alkyl (saturated hydrocarbons) as well as alkenyl and alkynyl moieties, having from 1 to about 20 (for example, from 1 to about 12, or 1 to about 6) carbon atoms.
- alkenyl and alkynyl moieties provides, among other things, the capability to cross-link the polyphosphazene moieties to any extent desired.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl and dodecyl.
- Cycloalkyl moieties may be monocyclic or multicyclic, and examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl. Additional examples of alkyl moieties have linear, branched and/or cyclic portions (e.g. 1-ethyl-4-methyl-cyclohexyl).
- R (alkyl) groups include unsubstituted alkyl, substituted alkyl such as halo-substituted alkyl (haloalkyl), unsubstituted alkenyl, substituted alkenyl such as halo-substituted alkenyl, and unsubstituted alkynyl, and substituted alkynyl such as halo-substituted alkynyl.
- alkoxy (OR) substituents can be unsubstituted alkoxy (“alkyloxy”), substituted alkoxy such as halo-substituted alkoxy (haloalkoxy), unsubstituted alkenyloxy, substituted alkenyloxy such as halo-substituted alkenyloxy, unsubstituted alkynyloxy, and substituted alkynyloxy such as halo-substituted alkynyloxy.
- vinyloxy and allyloxy can be useful.
- a silyl group is a —SiR 3 group and a silyloxy group is an —OSiR 3 group, where each R moiety is selected independently from the R groups defined supra. That is, R in each occurrence is selected independently from a linear, branched, and/or cyclic (“cycloalkyl”) hydrocarbyl moieties, including alkyl (saturated hydrocarbons) as well as alkenyl and alkynyl moieties, having from 1 to about 20 (for example, from 1 to about 12, or 1 to about 6) carbon atoms.
- cycloalkyl cyclic hydrocarbyl moieties, including alkyl (saturated hydrocarbons) as well as alkenyl and alkynyl moieties, having from 1 to about 20 (for example, from 1 to about 12, or 1 to about 6) carbon atoms.
- any R group can be unsubstituted or substituted independently with at least one substituent selected from a halogen (fluorine, chlorine, bromine, or iodine), an alkyl, an alkylsulfonyl, an amino, an alkylamino, a dialkylamino, an amidino (—N ⁇ C(NH 2 ) 2 ), an alkoxide, or an aryloxide, any of which can have up to about 6 carbon atoms, if applicable.
- a halogen fluorine, chlorine, bromine, or iodine
- an alkyl an alkylsulfonyl
- an amino, an alkylamino, a dialkylamino an amidino (—N ⁇ C(NH 2 ) 2 )
- an alkoxide or an aryloxide, any of which can have up to about 6 carbon atoms, if applicable.
- substituted “alkyl” and moieties which encompass substituted alkyl, such as “alkoxy,” include haloalkyl and haloalkoxy, respectively, including any fluorine-, chlorine-, bromine-, and iodine-substituted alkyl and alkoxy.
- haloalkyl and haloalkoxy refers to alkyl and alkoxy groups substituted with one or more halogen atoms, namely fluorine, chlorine, bromine, or iodine, including any combination thereof.
- aryl means an aromatic ring or an aromatic or partially aromatic ring system composed of carbon and hydrogen atoms, which may be a single ring moiety, or may contain multiple rings bound or fused together.
- aryl moieties include, but are not limited to, phenyl, anthracenyl, azulenyl, biphenyl, fluorenyl, indan, indenyl, naphthyl, phenanthrenyl, 1,2,3,4-tetrahydro-naphthalene, tolyl, and the like, any of which having up to about 20 carbon atoms.
- An aryloxy group refers to an —O(aryl) moiety.
- haloaryl and haloaryloxy refer to aryl and aryloxy groups, respectively, substituted with one or more halogen atoms, namely fluorine, chlorine, bromine, or iodine, including any combination thereof.
- a heterocyclic alkyl group with at least one nitrogen as a heteroatom refers to a non-aromatic heterocycle and includes a cycloalkyl or a cycloalkenyl moiety in which one or more of the atoms in the ring structure is nitrogen rather than carbon, and which may be monocyclic or multicyclic, and may include exo-carbonyl moieties and the like.
- heterocyclic alkyl group with nitrogen as a heteroatom examples include, but are not limited to, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydropyrimidinyl, morpholinyl, aziridinyl, imidazolidinyl, 1-pyrroline, 2-pyrroline, or 3-pyrroline, pyrrolidinonyl, piperazinonyl, hydantoinyl, piperidin-2-one, pyrrolidin-2-one, azetidin-2-one, and the like.
- these groups include heterocyclic exocyclic ketones as well.
- a heteroaryl group with at least one nitrogen as the heteroatom refers to an aryl moiety in which one or more of the atoms in the ring structure is nitrogen rather than carbon, and which may be monocyclic or multicyclic.
- heterocyclic alkyl group with nitrogen as a heteroatom include, but are not limited to, acridinyl, benzimidazolyl, quinazolinyl, benzoquinazolinyl, imidazolyl, indolyl, isothiazolyl, isoxazolyl, oxazolyl or oxadiazolyl, phthalazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolinyl, tetrazolyl, thiazolyl, triazinyl, and the like.
- this disclosure includes or encompasses chemical moieties found as subunits in a wide range of pharmaceutical agents, natural moieties, natural biomolecules, and biomacromolecules.
- this disclosure encompasses a number of pharmaceutical agents available with the tetrazole group (for example, losartan, candesartan, irbesartan, and other Angiotensin receptor antagonists); the triazole group (for example, fluconazole, isavuconazole, itraconazole, voriconazole, pramiconazole, posaconazole, and other antifungal agents); diazoles (for example, fungicides such as Miconazole, Ketoconazole, Clotrimazole, Econazole, Bifonazole, Butoconazole, Fenticonazole, Isoconazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, and the like); and imidazoles (h
- a heterocyclic alkyl group with at least one phosphorus, oxygen, sulfur, or selenium as a heteroatom refers to a non-aromatic heterocycle and includes a cycloalkyl or a cycloalkenyl moiety in which one or more of the atoms in the ring structure is phosphorus, oxygen, sulfur, or selenium rather than carbon, and which may be monocyclic or multicyclic, and may include exo-carbonyl moieties and the like.
- heteroaryl group with at least one phosphorus, oxygen, sulfur, or selenium as the heteroatom refers to an aryl moiety in which one or more of the atoms in the ring structure is phosphorus, oxygen, sulfur, or selenium rather than carbon, and which may be monocyclic or multicyclic.
- heterocyclic alkyl groups or heteroaryls with phosphorus, oxygen, sulfur, or selenium as a heteroatom include, but are not limited to, substituted or unsubstituted ethylene oxide (epoxides, oxiranes), oxirene, oxetane, tetrahydrofuran (oxolane), dihydrofuran, furan, pyran, tetrahydropyran, dioxane, dioxin, thiirane (episulfides), thietane, tetrahydrothiophene (thiolane) dihydrothiophene, thiophene, thiane, thiine (thiapyrane), oxazine, thiazine, dithiane, dithietane, and the like.
- substituted or unsubstituted ethylene oxide epoxides, oxiranes
- oxirene oxetane
- these groups include all isomers, including regioisomers of the recited compounds.
- these groups include 1,2- and 1,3-oxazoles, thiazoles, selenazoles, phosphazoles, and the like, which include different heteroatoms from the group 15 or group 16 elements.
- polymers other than the poly[bis(trifluoroethoxy) phosphazene] and/or its derivative may be included and/or combined with in the particle.
- examples of polymers may include poly(lactic acid), poly(lactic-co-glycolic acid), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyorthoesters, polyacetals, polycyanoacrylates, and polyurethanes.
- polymers include polyacrylates, ethylene-vinyl acetate co-polymers, acyl substituted cellulose acetates and derivatives thereof, degradable or non-degradable polyurethanes, polystyrenes, polyvinylchloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonated polyolefins, and polyethylene oxide.
- polyacrylates include, but are not limited to, acrylic acid, butyl acrylate, ethylhexyl acrylate, methyl acrylate, ethyl acrylate, acrylonitrile, methyl methacrylate, TMPTA (trimethylolpropane triacrylate), and the like.
- the particle may be coated with an additional polymer layer or layers, including polymers such as those mentioned hereinabove.
- PTFEP or derivatives thereof may be used to form such a coating on a particle formed of other suitable polymers or copolymers known or to be developed in the art.
- PTFEP is applied as a coating on a microparticle(s) formed of an acrylic-based polymer as set forth in further detail below.
- FIG. 4 is a schematic of an interventional occlusion of a hypothetical blood vessel employing particles of at least three different diameter sizes, each set of particles labeled according to a different color scheme.
- a hypothetical blood vessel 400 that can transport blood from point 405 to point 410 as shown. If occlusion of blood vessel 400 at point 410 , for example, is necessary for treatment, efficient occlusion can be achieved by deploying a first set A of smallest particles such as 420 and 422 , followed immediately by a second set B of intermediate particles such as 430 and 432 , followed immediately by a third set C of largest particles such as 440 and 442 of a given range of particles calibrated to a particular size of interest.
- a method of selective embolization at a site in need of comprising administering color-coded and size-calibrated particles described herein to a patient in need of.
- an alkyl substituent or group can have from 1 to 20 carbon atoms
- Applicants intent is to recite that the alkyl group have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms, including any range or sub-range encompassed therein.
- Applicants reserve the right to proviso out or exclude any individual members of such a group, including any sub-ranges or combinations of sub-ranges within the group, that can be claimed according to a range or in any similar manner, if for any reason Applicants choose to claim less than the full measure of the disclosure, for example, to account for a reference that Applicants are unaware of at the time of the filing of the application.
- Indigo dye can be incorporated into acrylate-based microparticles as follows.
- the vat can be prepared by mixing 5 g Indigo, 2.5 ml ethanol, 150 ml hot water, 6.5 ml concentrated sodium hydroxide solution and 7.5 g sodium dithionite. The mixture can be stirred for 15 minutes at 50-60° C. until the mixture converts to yellow-greenish.
- the concentrated solution can be given into 3 L of hot (50-60° C.) water with 3 ml of ammonia (25% solution) and additional 2 g of sodium dithionite. The amount of water can be varied from 0 to 31 to receive different color intensity. After stirring of the solution becomes yellow-greenish the particles can be added, and gently stirred for additional 15 minutes. After decanting and rinsing of the particles with water they become blue.
- Indigo red can be incorporated following the same protocol.
- Dyes containing sulfonic acid side groups can be incorporated into acrylate-based microparticles as follows. Dyes containing sulfonic acid side groups have a high capacity in precipitating with barium ions to form a water insoluble compound. For example, 3 ml Reactive Blue 21 (20 mg/ml physiological saline) can be added to 3 ml hydrated polymethylacrylate beads (400-600 ⁇ m) in physiological saline (total volume 6 ml). The suspension can be gently shaken for 10 to 15 min to reach diffusion equilibrium. Afterwards, the aqueous phase can be removed. 5 ml 0.5 molar aqueous barium chloride can be added to the particles and shaken over 30 min at ambient temperature.
- the suspension was stored over night at 70° C., than extensively washed with physiological saline until the solution remained optically colorless.
- the solution can be substituted by 0.5 molar barium chloride and heated for 30 min to approximately 125° C. at 1.5 bar. Afterwards the particles can be extensively washed with physiological saline.
- Different color intensities can be prepared by varying aqueous Reactive Blue 21 concentrations from 2 to 30 mg/ml physiological saline and from 0.5 ml to 5 ml hydrated polymethylacrylate beads.
- Dyes containing sulfonic acid side groups can be incorporated into acrylate-based microparticles as follows. Reactive Blue, Reactive Blue 4, Reactive Blue 19, Reactive Blue 163, Reactive Black 5, Reactive Yellow 86, Reactive Yellow 15, Reactive Orange 78, Reactive Red 11, Reactive Red 180, Chinolin Yellow, Allura Red AC, and any combinations thereof can be used to obtain different color shades by using mixtures of various ratios/percentage. Color intensities can be altered by varying the total dye amount (1 mg to 400 mg).
- a mixture of methyl methacrylate (MMA), allyl methacrylate (AMA), and the crosslinker triethyleneglycol dimethacrylate (TEGDMA) is copolymerized in presence of a radical initiator (lauroyl peroxide, LP) can be performed by suspension polymerization.
- a radical initiator laroyl peroxide, LP
- 200 g freshly destilled MMA, 670 mg LP, 2.875 g TEGDMA, and 10 g AMA can be mixed until a clear solution is obtained.
- the aqueous phase composed of 23 g polyvinylalcohol (PVA; 26/88), 5 g disodium hydrogen phosphate, and 290 mg sodium dihydrogen phosphate can be dissolved in 1000 ml deionized water.
- Polymerization can be performed by stirring at 130 rpm (initial 250 rpm for 5 to 10 min) at 67° C. for 1 h, than 2 h at 70° C., and finally 80° C. for 2 h. Particle sizes in the range of 50 to 1000 ⁇ m can be obtained.
- Hydrolysis can be performed with 5 g of the particles (taken from sieve fraction 212 to 350 ⁇ m) in 1500 ml ethylene glycol containing 75 g potassium hydroxide under reflux for 2 h. Afterwards, the particles can be washed extensively with deionized water until pH7 results. The water can be substituted by physiological saline, and osmolarity measured at 290 ⁇ 50 mOsmol/kg.
- 20 ml hydrated particles in physiological saline
- 20 ml hydrated particles can be colored by adding 150 mg Reactive Blue 4 and Reactive Blue 19, respectively.
- the first dyeing can be performed at ambient temperature, the latter reaction at 70° C.; after 14 h, the particles can be washed with physiological saline until the solution remains optically colorless.
- a mixture of methyl methacrylate (MMA), diallylurea (DAU) and the crosslinker triethyleneglycol dimethacrylate (TEGDMA) is copolymerized in presence of a radical initiator (lauroyl peroxide, LP) can be performed by suspension polymerization.
- a radical initiator laroyl peroxide, LP
- 100 g freshly distilled MMA, 330 mg LP, 1.43 g TEGDMA, and 1.0 g DAU can be mixed until a clear solution is obtained.
- the aqueous phase composed of 11.5 g polyvinylalcohol (PVA; 26/88), 2.5 g disodium hydrogen phosphate, and 145 mg sodium dihydrogen phosphate can be dissolved in 500 ml deionized water.
- Polymerization can be performed by stirring at 130 rpm (initial 250 rpm for 5 to 10 min) at 67° C. for 1 h, than 2 h at 70° C. and finally 80° C. for 2 h. Particle sizes in the range of 50 to 800 ⁇ m.
- Hydrolysis can be performed with 5 g of the particles in 1500 ml ethylene glycol containing 75 g potassium hydroxide under reflux for 2 h. Afterwards, the particles can be washed extensively with deionized water until pH of 7 results. The water can be substituted by physiological saline, and osmolarity measured at 290 ⁇ 50 mOsmol/kg.
- 20 ml hydrated particles in physiological saline
- 20 ml hydrated particles can be colored by adding 150 mg Reactive Blue 4 and Reactive Blue 19, respectively.
- the first dyeing can be performed at ambient temperature, the latter reaction at 70° C.; after 16 h, the particles can be washed with physiological saline until the solution remains optically colorless.
- Reactive Dyes can bind to nucleophilic groups such as amines (primary amines preferred) or hydroxyl groups.
- nucleophilic groups such as amines (primary amines preferred) or hydroxyl groups.
- amine groups primary amines preferred
- hydroxyl groups 100 mg dry particles can be hydrated in 5 ml deionized water for 10 to 15 min.
- 100 mg 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 100 ⁇ m ethylene diamine (EDA) can be added and shaken gently for 2 h at ambient temperature. After extensive washing with potable water the beads can be dyed in 5 ml deionized water by adding 200 mg Reactive Blue 4 and Reactive Blue 19, respectively.
- the first mixture can be kept at room temperature and the latter reaction at 70° C., both over night.
- the dye solution can be removed and the particles can be washed with potable water and afterwards 3-4 times with 8-9 ml 0.9% NaCl aq until the transport solution (TS) is almost colorless.
- Different color intensities can be prepared by varying EDA (20 ⁇ l to 200 ⁇ l), EDC (20 mg to 200 mg), and dye amount (10 mg to 40 0 mg); other colors can be also created by using Reactive Red 11, Reactive Red 180, Reactive Yellow 86, Reactive Yellow 15, Reactive Black 5, and Reactive Blue 21.
- a broader range of colors such as green, purple, and orange beads can be prepared as follows.
- various mixtures of dyes can be employed together to create the colors of interest, for example: (i) orange can be made by mixing red and yellow (ii) green can be made by mixing blue and yellow, and (iii) purple can be made by mixing blue and red.
- Dyes can be chosen within the same dye family (Remazol®: Reactive Yellow 15, Reactive Red 180, Reactive Black 5, Reactive Blue 21 and Reactive Blue 19; Procion®: Reactive Red 11, Reactive Yellow 86, Reactive Blue 4). Different color shades can be obtained by using mixtures of different ratios in the range of about 1:100 to about 100:1.
- Color intensities can be altered by varying EDA (20 ⁇ l to 200 ⁇ l), EDC (20 mg to 200 mg), and adjusting the total dye amount from about 10 mg to about 400 mg.
- a broader range of colors such as green, purple, pink, orange, grey, olive, smurf-blue, brown, ivory, black, burgundy, crimson, turquoise, orange beads can be prepared.
- Mixtures of at least two dyes can be utilized to create the described colors.
- Amino activated Reactive Yellow 86, Reactive Yellow 15, Reactive Blue 19, Reactive Red 180, Reactive Orange 78, Reactive Blue 163, Reactive Black 5, Reactive Blue 21, Reactive Blue 4, Reactive Blue 19, and Reactive Red 11 can be used. Different color shades can be obtained by using mixtures of all percentage ratios.
- Color intensities can be altered by varying EDC (20 mg to 500 mg), and adjusting the total dye amount from about 1 mg to about 400 mg.
- a broader range of colors such as green, purple, pink, orange, grey, olive, smurf-blue, brown, ivory, black, burgundy, crimson, turquoise, and orange beads can be prepared.
- additional dyeing procedures can be applied utilizing another dye.
- Amino activated Reactive Yellow 86, Reactive Yellow 15, Reactive Blue 19, Reactive Red 180, Reactive Orange 78, Reactive Blue 163, Reactive Black 5, Reactive Blue 21, Reactive Blue 4, Reactive Blue 19, and Reactive Red 11 can be utilized, for example.
- Different color shades can be obtained altering dye amounts (0.1 mg to 20 mg) during the different dyeing procedures.
- Color intensities can be altered by varying EDC (20 mg to 500 mg), and adjusting the total dye amount from about 1 mg to 100 mg.
- Approximately 20 ml particles (900 ⁇ m) can be immersed in 80 ml 0.9% aqueous sodium chloride solution (physiological saline). First 2.6 ml aqueous iron(III) chloride (45%) can be added to this suspension, and then followed by 4 ml of 1 molar aqueous iron(II) sulfate. The suspension can be gently shaken for 10 to 15 min to reach diffusion equilibrium. 100 ml of 0.1 molar aqueous sodium hydroxide solution (containing 0.9% sodium chloride) can be added drop wise to allow iron hydroxide precipitation. The particles can be extensively washed with physiological saline. Rusty colored particles can be obtained.
- Different color intensities can be prepared by varying aqueous iron(III) chloride (45%) from 0.1 ml to 10 ml, 1 molar aqueous iron(II) sulfate from 0.15 ml to 15.5 ml, and aqueous sodium hydroxide from 0.1 molar to 1 molar and 4 ml to 400 ml, respectively.
- the particles can be prepared as described above, substituting 0.1 to 1 molar aqueous ammonia (NH 3aq ) in the place of sodium hydroxide.
- Different color intensities can be prepared by varying aqueous iron(III) chloride (45%) from 0.1 ml to 10 ml, 1 molar aqueous iron(II) sulfate from 0.15 ml to 15.5 ml, and aqueous ammonia from 0.1 molar to 1 molar and 4 ml to 400 ml, respectively.
- Different color intensities can be prepared by varying saturated aqueous iron(II) sulfate from 0.1 ml to 10 ml, hydrogen peroxide concentration from 0.1% to 5% utilizing an amount from 0.5 ml to 10 ml.
Abstract
Description
- This application is a continuation-in-part of U.S. patent application Ser. No. 11/924,674, filed on Oct. 26, 2007, currently pending, which:
- is a continuation-in-part of U.S. patent application Ser. No. 11/257,535, filed Oct. 25, 2005, currently pending, which claims the benefit of U.S. Provisional Patent Applications: No. 60/621,729, filed Oct. 25, 2004; and the No. 60/684,307, filed May 24, 2005; and
- also which claims the benefit of U.S. Provisional Patent Application No. 60/962,015, filed Jul. 25, 2007;
- the entire disclosures of which are incorporated herein by reference.
- This disclosure relates to various polymeric particles incorporating chromophores and other agents of interest that can be employed as implantable devices in animal subjects, for various diagnostic and therapeutic applications.
- Various cosmetic, clinical, and interventional procedures involve in vivo administration of synthetic particles, manufactured in various sizes and compositions. For example, various blends of polymeric embolic particles can be introduced into the lumen of blood vessels to intentionally impede blood flow through various tissues/organs affected with physical trauma, tumor, or any condition in which blood-flow intervention can provide an effective and noninvasive form of temporary or permanent mode of therapy (“embolization”).
- In general, the manufactured products containing such synthetic particles require further manipulation by the practitioner prior to in vivo administration. The particle-based products provided by a manufacturer need to be combined with other reagents in order to make a final sample preparation suitable for in vivo administration. Substantial human errors can be inadvertently introduced during the preparatory procedures that may increase the overall risk associated with performing a given treatment. Practitioners need particles formulated to minimize various types of risks introduced during sample preparations for various particle-mediated diagnostic and/or therapeutic applications.
- Various embodiments are directed to color-coded and size-calibrated polymeric particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising polyphosphazenes of formula I, useful for various therapeutic and/or diagnostic procedures. In various embodiments, the color-coded and size-calibrated polymeric particles can be employed in any particle-mediated procedure, including as embolic agents, dermal fillers, and various implantable devices for a broad range of clinical and cosmetic applications. The incorporation of a particular chromophore formulation that correlates with a pre-determined size specificity for implantable and loadable polymeric particles (“color-coded and size-calibrated”) enables the visual detection and identification of particles exhibiting a particular size of interest, and minimizes the probability of user-introduced or procedural errors.
-
FIG. 1 is a schematic of an exemplary color-coded and size-calibrated polymeric particle comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising a polyphosphazene coating of formula I. -
FIG. 2 is an exemplary reaction scheme for the incorporation of reactive dye molecules by forming activated groups within reactive dye molecules before reacting with acrylate-based hydrogels in the presence of a coupling agent. -
FIG. 3 is an exemplary reaction scheme for the incorporation of reactive dye molecules by forming activated groups within acrylate-based hydrogels before reacting with reactive dye molecules. -
FIG. 4 is a schematic of an interventional occlusion of a hypothetical blood vessel employing particles of at least three different diameter sizes, each set of particles labeled according to a different color scheme. - In addition to the definition of terms provided below, the terms “a” or “an” can mean one or more of the referenced subject matter.
- The term “particle-mediated procedure” refers to any procedure that involves the utilization of disclosed particles in order to facilitate a diagnostic purpose and/or a therapeutic purpose. Exemplary particle-mediated procedures include various intravascular interventional procedures (“embolization”) involving in vivo administration of synthetically made particles of various compositions for reducing or stopping blood flow into the affected tissue/organ, including: for controlling gastrointestinal bleeding of any cause, for controlling bleeding into the abdomen or pelvis from any physical trauma injuries, for controlling bleeding resulting from long menstrual periods or heavy menstrual bleeding caused by uterine fibroid tumors, for occluding vessels that are supplying blood to tumors, for eliminating arteriovenous malformation (AVM) or arteriovenous fistula (AVF) caused by abnormal connection or connections between arteries and veins, for treating various types of aneurysms, and various other conditions and diseases suitable for such particle-mediated interventional procedures. The contemplated “particle-mediated procedures” include any procedure in which a benefit can be conferred by the targeted delivery of particles of interest for any form of therapy, including various diagnostic, therapeutic, and cosmetic applications. The particles can be delivered to any tissue or organ of a recipient. The type of optimal particles (size range, color, composition) suitable for a given condition under contemplation would need to be determined by the practitioner.
- The terms “particle(s),” “color-coded particles,” and “color-coded and size-calibrated particles” can be used interchangeably to refer to any synthetically made particle of any shape or surface contour, with an average diameter size ranging from approximately 10 μm to approximately 1500 μm, that can be employed for any particle-based procedure, and includes various embolic particles and dermal-filler particles. In various embodiments, the particles refer to substantially polymeric bodies shaped or formed as substantially spherical or ellipsoid articles manufactured to a particular size or diameter of interest and incorporating one or more chromophores of interest in order to produce a set of particles characterized by a particular predetermined size and color.
- The term “embolic particles” refers to any synthetically made particle of any shape or surface contour, with an average diameter size ranging from approximately 10 μm to approximately 1500 μm, suitable for any embolization procedure, and exemplifies “color-coded and size-calibrated particles.” In producing embolic particles of a broad size range, each set of particles calibrated for a particular size/dimension can be manufactured to incorporate a particular color desired to match the size-calibrated particles so that each set of such particles can be visually identified by the particular color exhibited (“color-coded”). Suitable embolic particles can be composed of any material amendable to controlled manufacturing and production specifications according to shaping and sizing requirements. Embolic particles are typically suspended in a transport medium containing various components that stabilize the particles during storage and shipment by manufacturers. In particular, the color-coded and size-calibrated particles can be employed as embolic agents for treating hypertrophic obstructive cardiomyopathy (HCM), having an average diameter size ranging from approximately 50 μm to approximately 90 μm, preferably from approximately 60 μm to approximately 80 μm, and most preferably from approximately 70 μm to approximately 75 μm.
- The term “dermal-filler particles” refers to any synthetically made particle of any shape or surface contour, with an average diameter size ranging from approximately 50 μm to approximately 500 μm, from approximately 50 μm to approximately 400 μm, from approximately 50 μm to approximately 300 μm, from approximately 50 μm to approximately 200 μm, suitable for any cosmetic application procedure, and exemplifies “color-coded and size-calibrated particles.” Suitable dermal-filler particles can be composed of any material amendable to controlled manufacturing and production specifications according to shaping and sizing requirements. Dermal-filler particles can be administered to a recipient in need of cosmetic and/or therapeutic enhancement in appearance, including the removal of wrinkles, dermal texture imperfections, dermal blot clots, dermal age-related disease or damage, and other equivalent conditions known by persons skilled in the art of dermal cosmetic enhancement and dermal diagnostic/clinical/therapeutic applications. Mixtures of chromophores formulated to resemble various skin tones can be incorporated into the acrylate-based hydrogel cores of color-coded and size-calibrated particles manufactured for use as dermal fillers.
- The term “acrylate-based hydrogel” refers to any polymer chain, formed in part or entirely, through the polymerization of an acrylate based monomer and (optionally) through subsequent and/or parallel reactions, can be three-dimensionally crosslinked, and having pendant side groups to confer the resulting cross-linked polymeric network with a substantial affinity for particular solvents, such as water, and to enable swelling.
- The term “gel” refers to an elastic colloid or polymeric network capable of expanding throughout the volume by the absorption of fluid. The polymer network can be a network formed by covalent bonds or by physical aggregation with region of local order acting as network junctions. Both by weight and volume, gels can be mostly liquid in composition and thus exhibit densities similar to that of liquids, however, gels have the structural coherence of a solid. The term “hydrogel” refers to a polymeric network capable of absorbing water.
- The term “crosslink” refers to a small region in a macromolecule from which at least three chains emanate, and formed by reactions involving sites or groups on existing macromolecules or by interactions between existing macromolecules. The small region may be an atom, a group of atoms, or a number of branch points connected by bonds, groups of atoms, or oligomeric chains. In general, a crosslink is a covalent structure but the term can describe sites of weaker chemical interactions, portions of crystallites, and even physical entanglements.
- The term “chromophores” refers to any molecule that can absorb certain wavelengths of visible light, and can transmit or reflect other wavelengths as understood by persons skilled in the art, and includes various nontoxic pigments and dyes of medical grade that can be incorporated into food and/or medical devices for implantation into human and/or animal subjects without imposing the risk of substantial harm The chromophores suitable for incorporation into particles of interest include dyes that have been approved or have been exempt from certification by the FDA, which are listed under TITLE 21—FOOD AND DRUGS, CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SUBCHAPTER A, GENERAL, PART 73 LISTING OF COLOR ADDITIVES EXEMPT FROM CERTIFICATION, Subpart D—Medical Devices, the disclosure of which is incorporated herein by reference.
- The term “incorporate” refers to any process involving the physical or chemical affixation of one or more species, including atoms, molecular entities, agents such as dyes, oligo- and polymeric species together. For example, the term refers to processes involving impregnation, precipitation, covalent binding, grafting in- or onto, fixing in- or onto, diffusion, permeation, temporary or permanent, partial or complete localization within, around, throughout a given article.
- In various embodiments, the color-coded and size-calibrated polymeric particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising polyphosphazenes of formula I, useful for various therapeutic and/or diagnostic procedures are provided.
- In various embodiments, the color-coded and size-calibrated polymeric particles, comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest and an outer shell comprising polyphosphazenes of formula I, can be employed as embolic particles for mediating various interventional procedures.
- In various embodiments, the color-coded and size-calibrated polymeric particles, comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest and an outer shell comprising polyphosphazenes of formula I, can be employed as embolic agents for treating hypertrophic obstructive cardiomyopathy (HCM).
- In various embodiments, the color-coded and size-calibrated polymeric particles, comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest and an outer shell comprising polyphosphazenes of formula I, can be employed as dermal fillers.
- In various embodiments, the biocompatible and loadable polymeric particles comprises an acrylate-based hydrogel core incorporating one or more chromophores of interest and an outer shell comprising poly[bis(trifluoroethoxy) phosphazene] and/or a derivative thereof. The incorporation of a particular chromophore formulation that correlates with a predetermined size range of implantable and loadable polymeric particles of interest (“color-coded” particles) permit a convenient and accurate visual identification of particles of interest and minimizes user-introduced errors.
- 1. Acrylate-Based Hydrogels
-
FIG. 1 is a schematic of an exemplary color-coded and size-calibrated polymeric particle comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising a polyphosphazene coating of formula I. InFIG. 1 , ahypothetical particle 100 comprising an acrylate-based hydrogel core 110 and anouter shell 120 is shown. The acrylate-based hydrogel core 110 can be manufactured to incorporate various chromophores present in a sufficient amount to permit the detection of a “color” by a human eye or by an instrument. The total amount of chromophores sufficient to be visually detected can vary depending on particular chromophores selected. The total amount of chromophores that can be incorporated into the color-coded and size-calibrated particles can range up to about 20%, about 15%, about 10%, about 8%, about 6%, about 5%, or about 2.5% of the total dry weight of the hydrogel. Anouter shell 120 comprising at least one polyphosphazene of formula I, can be formed on the surface of the acrylate-based hydrogel core 110 to provide a biocompatible coating layer. - In various embodiments, the color-coded and size-calibrated polymeric particles can be manufactured to be substantially uniform in size. For example, the smallest average diameter of a set of particles for a first product line can be about 10 μm, and the largest average diameter of a set of particles for a second product line can be about 1500 μm. The average diameter size range of particles of interest can be selected from about 10 μm to about 1500 μm; from about 10 μm to about 1100 μm; from about 10 μm to about 1000 μm; from about 10 μm to about 900 μm; from about 10 μm to about 800 μm; from about 10 μm to about 700 μm; from about 10 μm to about 600 μm; from about 10 μm to about 500 μm; from about 10 μm to about 400 μm; from about 10 μm to about 300 μm; from about 10 μm to about 200 μm; from about 10 μm to about 175 μm; from about 10 μm to about 150 μm; from about 10 μm to about 120 μm; from about 10 μm to about 80 μm; and from about 10 μm to about 40 μm. Suitable range in average diameter size of a particle of interest include: from about 20 μm to about 1500 μm; from about 20 μm to about 1200 μm; from about 20 μm to about 1000 μm; from about 20 μm to about 900 μm; from about 20 μm to about 800 μm; from about 20 μm to about 700 μm; from about 20 μm to about 600 μm; from about 20 μm to about 500 μm; from about 20 μm to about 400 μm; from about 20 μm to about 300 μm; from about 20 μm to about 200 μm; from about 20 μm to about 175 μm; from about 20 μm to about 150 μm; from about 20 μm to about 120 μm; from about 20 μm to about 80 μm; and from about 20 μm to about 40 μm. Suitable range in average diameter size of a particle of interest include: from about 30 μm to about 1500 μm; from about 30 μm to about 1300 μm; from about 30 μm to about 3000 μm; from about 30 μm to about 900 μm; from about 30 μm to about 800 μm; from about 30 μm to about 700 μm; from about 30 μm to about 600 μm; from about 30 μm to about 500 μm; from about 30 μm to about 400 μm; from about 30 μm to about 300 μm; from about 30 μm to about 300 μm; from about 30 μm to about 175 μm; from about 30 μm to about 150 μm; from about 30 μm to about 130 μm; from about 30 μm to about 80 μm; and from about 30 μm to about 40 μm. The color-coded and size-calibrated polymeric particles can be calibrated to a predetermined deviation tolerance of less than or equal to about ±5%, less than or equal to about ±10%, less than or equal to about ±15%, less than or equal to about ±20%, less than or equal to about ±25%, less than or equal to about ±30%, or less than or equal to about ±35% from the design specification. In a preferred embodiment, the color-coded and size-calibrated polymeric particles can be manufactured to exhibit a narrow size distribution proportional to the average size of the particles. For example, the particles within the range from about 700 μm to about 1000 μm can vary less than or equal to only about ±3-5% from the design specification, whereas particles within the size range from about 40 μm to about 100 μm can vary less than or equal to about ±20-25% from the design specification.
- In another embodiment, the color-coded and size-calibrated polymeric particles can be manufactured to exhibit uniformity in shape, and preferably, the particles can be manufactured to be substantially spherical in shape.
- Various methods for manufacturing acrylate-based hydrogel cores have been previously described by the present Applicants in U.S. Patent Publication Nos. 2006/0088476 and 2008/0113029, the entire disclosures of which are incorporated herein by reference.
- 2. Acrylate-Based Hydrogels as the Core Component of Color-Coded and Size-Calibrated Particles
- The color-coded and size-calibrated polymeric particles comprise an acrylate-based hydrogel, as a core component, that can be manufactured utilizing various polymers known to persons skilled in the art, including polymers selected from poly(methacrylic acid), poly(methyl acrylate), poly(methyl methacrylate) (PMMA), poly(ethyl methacrylate), poly(hexamethyl methacrylate), poly(hydroxyethyl methacrylate), poly(acrylic acid), poly(butyl acrylate), poly(2-ethylhexyl acrylate), poly(ethyl acrylate), poly(acrylonitrile), poly(trimethylolpropane triacrylate), or an equivalent known by persons skilled in the art, a copolymer thereof, and/or a combination thereof.
- 3. Exemplary Chromophores and Methods for Incorporating into Acrylate-Based Hydrogels
-
FIG. 2 is an exemplary reaction scheme for the incorporation of reactive dye molecules by forming activated groups within reactive dye molecules before reacting with acrylate-based hydrogels in the presence of a coupling agent. InFIG. 2 , a suitable reactive dye 200 can be amino-activated with an aliphatic diamine (ethylene diamine) 210 to form an aliphatic amino group within the reactive dye 220, which can be reacted with a hypothetical acrylate-based hydrogel 230 in the presence of a coupling promoter agent 240, such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), to produce color-coded and size-calibrated particles 250 incorporated with reactive dye molecules by a stable covalent linkage. - Table of Exemplary Reactive Dyes:
-
Table of Exemplary Reactive Dyes: Monochlorotriazines R1 = chromophore R2 = 2nd chromophore or any other Mono- fluorochlorotriazines R = chromophore Dichlorotriazines R = chromophore Dichloroquinoxaline R1 = chromophore or any other R2 = chromophore or any other R3 = chromophore or any other R4 = chromophore or any other Trichloropyrimidine R = chromophore Vinyl sulfone R = chromophore Vinyl amide R1 = chromophore or any other R2 = chromophore or any other R3 = chromophore or any other R4 = chromophore or any other - Exemplary reactive dyes used in production (FDA exempt from certification): Reactive Red 11 (dichlorotriazine), Reactive Yellow 86 (dichlorotriazine), Reactive Blue 4 (dichlorotriazine), Reactive Black 5 (vinyl sulfone), Reactive Red 180 (vinyl sulfone), Reactive Yellow 15 (vinyl sulfone), Reactive Blue 19 (vinyl sulfone), Reactive Blue 21 (vinyl sulfone), Reactive Blue 163 (vinyl sulfone), Reactive Orange 78 (vinyl sulfone), and others known to persons skilled in the art.
- Exemplary spacer molecules to link the reactive dye to the polymer in the hydrogel include any di-functional, tri-functional, or multi-functional species, the functional species comprising a nucleophilic group, including H2N—(CH2)n—NH2 (n≧2) [in production n=2 (ethylene diamine)], [H—2N—(CH2)n]3—CH (n≧1), [H2N—(CH2)n]4—C (n≧1). These examples can be accordingly reformulated by replacing the nucleophilic group H2N— with —OH, —SH or any other arbitrary nucleophilic group.
- An exemplary formula for an amino activator spacer molecule is provided by: H2N—CH2—R—CH2—NH2, wherein the R is an alkylene, alkoxylene, alkenylene, alkinylene, arylene, and alkylarylene; includes carrying organic and heteroorganic side groups (such as hydroxyl, silyl, thiol, sulfonyl, sulfoxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate).
-
FIG. 3 is an exemplary reaction scheme for the incorporation of reactive dye molecules by forming activated groups within acrylate-based hydrogels before reacting with reactive dye molecules. In the first reaction ofFIG. 3 , the carboxylic acid groups of the PMAA 300, as an hypothetical acrylate-based hydrogel, can be amino-activated by reacting with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 310 in the presence of an aliphatic diamine (ethylene diamine) 320. In the second reaction ofFIG. 3 , the resulting free amino group within the activated acrylate-based hydrogel 330 can react with the reactive dyes 340 to produce the color-coded and size-calibrated particles 350 incorporated with reactive dye molecules by a stable covalent linkage. - Alternatively, active anchor groups can be created within the PMAA core of color-coded and size-calibrated particles during the polymerization process of PMMA. For example, co-polymerization of MMA in the presence of a small amount (about 1-10%) of amino (—NH2) or hydroxyl (—OH) groups (or protected forms of both) containing unsaturated species can generate active anchor groups so that reactive dyes can be directly bound to the hydrogel core without prior activation without requiring ethylene diamine via EDC to activate the hydrogel core or amino activation of dye molecules. Exemplary co-polymers include unsaturated alcohols, unsaturated amines, and unsaturated thiols.
- The generalized formula for unsaturated alcohols is R5O—R1—CR2═CR3R4
- wherein R1 is any bivalent group with no electron withdrawing impact on —OH; this includes but is not limited to alkylene, alkoxylene, alkenylene, alkinylene, arylene, and alkylarylene, also including organic and heteroorganic side groups (e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate);
- wherein R2, R3 and/or R4 enable copolymerization and include but are not limited to hydrogen, halogen, alkyl, alkoxyl, alkenyl, alkinyl, aryl, and alkylaryl, or any combinations or derivatives thereof, also including any organic and heteroorganic side groups (e.g. silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate); and
- wherein R5 includes hydrogen or any protecting group.
- Exemplary unsaturated alcohols include vinyl alcohol (H2C═CH—OH) or derivatives [H2C═CH—(CH2)n—OH] (n≧1) [n=1: allyl alcohol].
- The generalized formula for unsaturated amine is: R5HN—R1—CR2═CR3R4
- wherein R1 is any bivalent group with no electron withdrawing impact on —OH; this includes but is not limited to alkylene, alkoxylene, alkenylene, alkinylene, arylene, and alkylarylene, also including organic and heteroorganic side groups (e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate);
- wherein R2, R3 and/or R4 enable copolymerization and include but are not limited to hydrogen, halogen, alkyl, alkoxyl, alkenyl, alkinyl, aryl, and alkylaryl, or any combinations or derivatives thereof, also including any organic and heteroorganic side groups (e.g. silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate); and
- wherein R5 includes hydrogen or any protecting group.
- Exemplary unsaturated amines include vinyl amine (H2C═CH—NH2) or derivatives [H2C═CH—(CH2)n—NH2] (n≧1).
- The generalized formula for unsaturated thiols is R5S—R1—CR2═CR3R4
- wherein R1 is any bivalent group with no electron withdrawing impact on —OH; this includes but is not limited to alkylene, alkoxylene, alkenylene, alkinylene, arylene, and alkylarylene, also including organic and heteroorganic side groups (e.g. hydroxyl, silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate);
- wherein R2, R3 and/or R4 enable copolymerization and include but are not limited to hydrogen, halogen, alkyl, alkoxyl, alkenyl, alkinyl, aryl, and alkylaryl, or any combinations or derivatives thereof, also including any organic and heteroorganic side groups (e.g. silyl, thiol, sulfonyl, suloxyl, sulfate, amine, immine, amide, nitro, nitroso, phosphine, phosphonate, phosphate); and
- wherein R5 includes hydrogen or any protecting group.
- Exemplary unsaturated amines include vinyl mercaptane (H2C═CH—SH) or derivatives [H2C═CH—(CH2)n—SH] (n≧1) [n=1: allyl mercaptane].
- 4. Exemplary Agents of Interest
- In various embodiments, the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate any compound/agent of interest suitable for various therapeutic and/or diagnostic applications.
- In various embodiments, the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate any bioactive and pharmaceutical agents, such as peptides, proteins, hormones, carbohydrates, polysaccharides, nucleic acids, lipids, vitamins, steroids, organic or inorganic drugs, and/or equivalents, and combinations thereof.
- In various embodiments, the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate various fluorescent dyes, radiopaque reagents, and/or equivalents to permit contemporaneous monitoring, and combinations thereof.
- In various embodiments, the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate magnetic, diamagnetic, paramagnetic, ferromagnetic and/or antiferromagnetic elements to impart certain magnetic properties.
- In various embodiments, the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate various excipients, such as dextranes, other sugars, polyethylene glycol, glucose, and various salts. The term “contrast agent” refers to various compounds, suspended in contrast medium/media, that enables radiopaque visibility by highlighting specific tissue/organ of interest during various diagnostic medical imaging examinations and/or treatment procedures that require simultaneous monitoring, by various means including: x-ray exams, computed tomography scans, and magnetic resonance imaging. Exemplary contrast agents include iobitridol, iodixanol, iomeprol, iopamidol, iopentol, iopromide, ioversol, and other iodine-formulated compositions, which have iodine concentrations between about 240 mg/ml to about 400 mg/ml, or more. In general, as the average size of particles increases, a larger volume of contrast medium may be required to sufficiently saturate the particles with an iodine threshold level necessary to provide adequate radiopaque visibility when monitoring particle transport following in vivo administration.
- In various embodiments, the acrylate-based hydrogel core of the color-coded and size-calibrated particles can incorporate barium sulfate, which can be utilized for increasing the density of the particle, so that the particle can be properly suspended within a dense medium, such as a contrast agent-containing solution, for modulating or enhancing the added chromophore by creating varying degrees of translucency, contributing to the intensity of the color perceived, for changing the elastic and mechanic properties of a particle as an inelastic component, and/or for increasing the radiopaqueness of a particle, without the use of separate contrast agent, capable of acting as a contrast agent in itself.
- The definition for high molecular weight polyphosphazenes of formula I and methods for coating acrylate-based hydrogel cores have been previously described by the present Applicants in U.S. Patent Publication Nos. 2006/0088476 and 2008/0113029, the entire disclosures of which are incorporated herein by reference.
- Various embodiments are directed to color-coded and size-calibrated particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising polyphosphazenes having the general formula (I):
-
- in which the n value is an integer from 2 to ∞;
- R1 to R6 are independently selected from the group consisting of:
- a substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy, silyl, silyloxy, alkylsulfonyl, alkyl amino, dialkyl amino, ureido, carboxylic acid ester, alkylmonoamidine, alkylbisamidine, alkoxymonoamidine, alkoxybisamidine; and an amino;
- a heterocyclic alkyl group with at least one nitrogen, phosphorus, oxygen, sulfur, or selenium as a heteroatom;
- a heteroaryl group with at least one nitrogen, phosphorus, oxygen, sulfur, or selenium as the heteroatom;
- a nucleotide or a nucleotide residue;
- a biomacromolecule; and
- a pyrimidine or a purine base.
- Suitable substituents for R1 to R6 can be independently selected from the group consisting of: halide substituents, such as fluorine, chlorine bromine, or iodine; pseudohalide substituents, such as cyano (—CN), isocyano (—NC), thiocyano (—SCN), isothiocyano (—NCS), cyanato (—OCN), isocyanato (—NCO), or azido (—N3) groups; substituents such as nitro- (—NO2) or nitrito (—NO) groups; partially substituted alkyl groups, such as haloalkyl; heteroaryl such as imidazoyl, oxazolyl, thiazolyl, or pyrazolyl derivatives; and purine and pyrimidine bases such as guanidines, amidines or other ureido derivatives of the base structure.
- As used herein, alkyl (R), alkoxy (—OR), alkylsulfonyl (—SO2R), alkyl amino (—NHR), dialkyl amino (—NR2), carboxylic acid ester (-(alkadiyl)C(O)OR or -alkadiyl)OC(O)R)), ureido (—NHC(O)NH2, —NRC(O)NH2, —NHC(O)NHR, —NRC(O)NHR, —NHC(O)NR2, —NRC(O)NR2, and their alkadiyl-linked analogs), alkylmonoamidine (including —N═C(NR2)R, —(alkadiyl)N═C(NR2)R, —C(NR2)═NR, and -(alkadiyl)C(NR2)═NR), alkylbisamidine (including —N═C(NR2)2, -(alkadiyl)N═C(NR2)2, —NRC(NR2)═NR, and -(alkadiyl)NRC(NR2)═NR), alkoxymonoamidine (—O(alkadiyl)N═C(NR2)R, —OC(NR2)═NR, and —O(alkadiyl)C(NR2)═NR)), and alkoxybisamidine (—O(alkadiyl)N═C(NR2)2. —O(alkadiyl)NRC(NR2)—NR, and —O(alkadiyl)NRC(NR2)═NR) moieties are defined by the corresponding formula shown, in which R can be selected independently from a linear, branched, and/or cyclic (“cycloalkyl”) hydrocarbyl moieties, including alkyl (saturated hydrocarbons) as well as alkenyl and alkynyl moieties, having from 1 to about 20 (for example, from 1 to about 12, or 1 to about 6) carbon atoms.
- The inclusion of alkenyl and alkynyl moieties provides, among other things, the capability to cross-link the polyphosphazene moieties to any extent desired. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl and dodecyl. Cycloalkyl moieties may be monocyclic or multicyclic, and examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl. Additional examples of alkyl moieties have linear, branched and/or cyclic portions (e.g. 1-ethyl-4-methyl-cyclohexyl).
- According to this definition and usage (supra), specific examples of R (alkyl) groups include unsubstituted alkyl, substituted alkyl such as halo-substituted alkyl (haloalkyl), unsubstituted alkenyl, substituted alkenyl such as halo-substituted alkenyl, and unsubstituted alkynyl, and substituted alkynyl such as halo-substituted alkynyl.
- Furthermore, these examples of R (alkyl) provide that the alkoxy (OR) substituents can be unsubstituted alkoxy (“alkyloxy”), substituted alkoxy such as halo-substituted alkoxy (haloalkoxy), unsubstituted alkenyloxy, substituted alkenyloxy such as halo-substituted alkenyloxy, unsubstituted alkynyloxy, and substituted alkynyloxy such as halo-substituted alkynyloxy. In this aspect, vinyloxy and allyloxy can be useful.
- A silyl group is a —SiR3 group and a silyloxy group is an —OSiR3 group, where each R moiety is selected independently from the R groups defined supra. That is, R in each occurrence is selected independently from a linear, branched, and/or cyclic (“cycloalkyl”) hydrocarbyl moieties, including alkyl (saturated hydrocarbons) as well as alkenyl and alkynyl moieties, having from 1 to about 20 (for example, from 1 to about 12, or 1 to about 6) carbon atoms.
- Unless otherwise specified, any R group can be unsubstituted or substituted independently with at least one substituent selected from a halogen (fluorine, chlorine, bromine, or iodine), an alkyl, an alkylsulfonyl, an amino, an alkylamino, a dialkylamino, an amidino (—N═C(NH2)2), an alkoxide, or an aryloxide, any of which can have up to about 6 carbon atoms, if applicable. Thus, the term substituted “alkyl” and moieties which encompass substituted alkyl, such as “alkoxy,” include haloalkyl and haloalkoxy, respectively, including any fluorine-, chlorine-, bromine-, and iodine-substituted alkyl and alkoxy. Thus, terms haloalkyl and haloalkoxy refers to alkyl and alkoxy groups substituted with one or more halogen atoms, namely fluorine, chlorine, bromine, or iodine, including any combination thereof.
- Unless otherwise indicated, the term “aryl” means an aromatic ring or an aromatic or partially aromatic ring system composed of carbon and hydrogen atoms, which may be a single ring moiety, or may contain multiple rings bound or fused together. Examples of aryl moieties include, but are not limited to, phenyl, anthracenyl, azulenyl, biphenyl, fluorenyl, indan, indenyl, naphthyl, phenanthrenyl, 1,2,3,4-tetrahydro-naphthalene, tolyl, and the like, any of which having up to about 20 carbon atoms. An aryloxy group refers to an —O(aryl) moiety.
- The terms haloaryl and haloaryloxy refer to aryl and aryloxy groups, respectively, substituted with one or more halogen atoms, namely fluorine, chlorine, bromine, or iodine, including any combination thereof.
- A heterocyclic alkyl group with at least one nitrogen as a heteroatom refers to a non-aromatic heterocycle and includes a cycloalkyl or a cycloalkenyl moiety in which one or more of the atoms in the ring structure is nitrogen rather than carbon, and which may be monocyclic or multicyclic, and may include exo-carbonyl moieties and the like. Examples of heterocyclic alkyl group with nitrogen as a heteroatom include, but are not limited to, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydropyrimidinyl, morpholinyl, aziridinyl, imidazolidinyl, 1-pyrroline, 2-pyrroline, or 3-pyrroline, pyrrolidinonyl, piperazinonyl, hydantoinyl, piperidin-2-one, pyrrolidin-2-one, azetidin-2-one, and the like. Thus, these groups include heterocyclic exocyclic ketones as well.
- A heteroaryl group with at least one nitrogen as the heteroatom refers to an aryl moiety in which one or more of the atoms in the ring structure is nitrogen rather than carbon, and which may be monocyclic or multicyclic. Examples of heterocyclic alkyl group with nitrogen as a heteroatom include, but are not limited to, acridinyl, benzimidazolyl, quinazolinyl, benzoquinazolinyl, imidazolyl, indolyl, isothiazolyl, isoxazolyl, oxazolyl or oxadiazolyl, phthalazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolinyl, tetrazolyl, thiazolyl, triazinyl, and the like. In this aspect, this disclosure includes or encompasses chemical moieties found as subunits in a wide range of pharmaceutical agents, natural moieties, natural biomolecules, and biomacromolecules. For example, this disclosure encompasses a number of pharmaceutical agents available with the tetrazole group (for example, losartan, candesartan, irbesartan, and other Angiotensin receptor antagonists); the triazole group (for example, fluconazole, isavuconazole, itraconazole, voriconazole, pramiconazole, posaconazole, and other antifungal agents); diazoles (for example, fungicides such as Miconazole, Ketoconazole, Clotrimazole, Econazole, Bifonazole, Butoconazole, Fenticonazole, Isoconazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, and the like); and imidazoles (histidine, histamine, and the like). Thus in one aspect, some of the R1 to R6 moieties in the formula I can encompass chemical moieties found as subunits in a wide range of pharmaceutical agents, natural moieties, natural biomolecules, and biomacromolecules.
- A heterocyclic alkyl group with at least one phosphorus, oxygen, sulfur, or selenium as a heteroatom refers to a non-aromatic heterocycle and includes a cycloalkyl or a cycloalkenyl moiety in which one or more of the atoms in the ring structure is phosphorus, oxygen, sulfur, or selenium rather than carbon, and which may be monocyclic or multicyclic, and may include exo-carbonyl moieties and the like. Similarly, a heteroaryl group with at least one phosphorus, oxygen, sulfur, or selenium as the heteroatom refers to an aryl moiety in which one or more of the atoms in the ring structure is phosphorus, oxygen, sulfur, or selenium rather than carbon, and which may be monocyclic or multicyclic. Examples of heterocyclic alkyl groups or heteroaryls with phosphorus, oxygen, sulfur, or selenium as a heteroatom include, but are not limited to, substituted or unsubstituted ethylene oxide (epoxides, oxiranes), oxirene, oxetane, tetrahydrofuran (oxolane), dihydrofuran, furan, pyran, tetrahydropyran, dioxane, dioxin, thiirane (episulfides), thietane, tetrahydrothiophene (thiolane) dihydrothiophene, thiophene, thiane, thiine (thiapyrane), oxazine, thiazine, dithiane, dithietane, and the like. Thus, these groups include all isomers, including regioisomers of the recited compounds. For example, these groups include 1,2- and 1,3-oxazoles, thiazoles, selenazoles, phosphazoles, and the like, which include different heteroatoms from the group 15 or group 16 elements.
- Additionally, if desired, polymers other than the poly[bis(trifluoroethoxy) phosphazene] and/or its derivative may be included and/or combined with in the particle. Examples of polymers may include poly(lactic acid), poly(lactic-co-glycolic acid), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyorthoesters, polyacetals, polycyanoacrylates, and polyurethanes. Other polymers include polyacrylates, ethylene-vinyl acetate co-polymers, acyl substituted cellulose acetates and derivatives thereof, degradable or non-degradable polyurethanes, polystyrenes, polyvinylchloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonated polyolefins, and polyethylene oxide. Examples of polyacrylates include, but are not limited to, acrylic acid, butyl acrylate, ethylhexyl acrylate, methyl acrylate, ethyl acrylate, acrylonitrile, methyl methacrylate, TMPTA (trimethylolpropane triacrylate), and the like. One may incorporate the selected compounds by any means known in the art, including diffusing, inserting or entrapping the additional compounds in the matrix of an already formed particle or by adding the additional compound to a polymer melt or to a polymer solvent in the preparation of the particle such as described herein.
- The particle may be coated with an additional polymer layer or layers, including polymers such as those mentioned hereinabove. Further, PTFEP or derivatives thereof, may be used to form such a coating on a particle formed of other suitable polymers or copolymers known or to be developed in the art. Preferably, when coating a particle such as a microparticle, PTFEP is applied as a coating on a microparticle(s) formed of an acrylic-based polymer as set forth in further detail below.
-
FIG. 4 is a schematic of an interventional occlusion of a hypothetical blood vessel employing particles of at least three different diameter sizes, each set of particles labeled according to a different color scheme. InFIG. 4 , ahypothetical blood vessel 400 that can transport blood frompoint 405 to point 410 as shown. If occlusion ofblood vessel 400 atpoint 410, for example, is necessary for treatment, efficient occlusion can be achieved by deploying a first set A of smallest particles such as 420 and 422, followed immediately by a second set B of intermediate particles such as 430 and 432, followed immediately by a third set C of largest particles such as 440 and 442 of a given range of particles calibrated to a particular size of interest. - A method of selective embolization at a site in need of, the method comprising administering color-coded and size-calibrated particles described herein to a patient in need of.
- All publications and patents mentioned in this disclosure are incorporated herein by reference in their entireties, for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications, which might be used in connection with the presently described methods, compositions, articles, and processes. The publications discussed throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention. Should the usage or terminology used in any reference that is incorporated by reference conflict with the usage or terminology used in this disclosure, the usage and terminology of this disclosure controls. The Abstract of the disclosure is provided to satisfy the requirements of 37 C.F.R. §1.72 and the purpose stated in 37 C.F.R. §1.72(b) “to enable the United States Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure.” The Abstract is not intended to be used to construe the scope of the appended claims or to limit the scope of the subject matter disclosed herein. Moreover, any headings are not intended to be used to construe the scope of the appended claims or to limit the scope of the subject matter disclosed herein. Any use of the past tense to describe an example otherwise indicated as constructive or prophetic is not intended to reflect that the constructive or prophetic example has actually been carried out.
- Also unless indicated otherwise, when a range of any type is disclosed or claimed, for example a range of molecular weights, layer thicknesses, concentrations, temperatures, and the like, it is intended to disclose or claim individually each possible number that such a range could reasonably encompass, including any sub-ranges encompassed therein. For example, when the Applicants disclose or claim a chemical moiety having a certain number of atoms, for example carbon atoms, Applicants' intent is to disclose or claim individually every possible number that such a range could encompass, consistent with the disclosure herein. Thus, by the disclosure that an alkyl substituent or group can have from 1 to 20 carbon atoms, Applicants intent is to recite that the alkyl group have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms, including any range or sub-range encompassed therein. Accordingly, Applicants reserve the right to proviso out or exclude any individual members of such a group, including any sub-ranges or combinations of sub-ranges within the group, that can be claimed according to a range or in any similar manner, if for any reason Applicants choose to claim less than the full measure of the disclosure, for example, to account for a reference that Applicants are unaware of at the time of the filing of the application.
- Indigo dye can be incorporated into acrylate-based microparticles as follows. The vat can be prepared by mixing 5 g Indigo, 2.5 ml ethanol, 150 ml hot water, 6.5 ml concentrated sodium hydroxide solution and 7.5 g sodium dithionite. The mixture can be stirred for 15 minutes at 50-60° C. until the mixture converts to yellow-greenish. The concentrated solution can be given into 3 L of hot (50-60° C.) water with 3 ml of ammonia (25% solution) and additional 2 g of sodium dithionite. The amount of water can be varied from 0 to 31 to receive different color intensity. After stirring of the solution becomes yellow-greenish the particles can be added, and gently stirred for additional 15 minutes. After decanting and rinsing of the particles with water they become blue. Alternatively, Indigo red can be incorporated following the same protocol.
- Dyes containing sulfonic acid side groups can be incorporated into acrylate-based microparticles as follows. Dyes containing sulfonic acid side groups have a high capacity in precipitating with barium ions to form a water insoluble compound. For example, 3 ml Reactive Blue 21 (20 mg/ml physiological saline) can be added to 3 ml hydrated polymethylacrylate beads (400-600 μm) in physiological saline (total volume 6 ml). The suspension can be gently shaken for 10 to 15 min to reach diffusion equilibrium. Afterwards, the aqueous phase can be removed. 5 ml 0.5 molar aqueous barium chloride can be added to the particles and shaken over 30 min at ambient temperature. The suspension was stored over night at 70° C., than extensively washed with physiological saline until the solution remained optically colorless. The solution can be substituted by 0.5 molar barium chloride and heated for 30 min to approximately 125° C. at 1.5 bar. Afterwards the particles can be extensively washed with physiological saline. Different color intensities can be prepared by varying aqueous Reactive Blue 21 concentrations from 2 to 30 mg/ml physiological saline and from 0.5 ml to 5 ml hydrated polymethylacrylate beads.
- Dyes containing sulfonic acid side groups can be incorporated into acrylate-based microparticles as follows. Reactive Blue, Reactive Blue 4, Reactive Blue 19, Reactive Blue 163, Reactive Black 5, Reactive Yellow 86, Reactive Yellow 15, Reactive Orange 78, Reactive Red 11, Reactive Red 180, Chinolin Yellow, Allura Red AC, and any combinations thereof can be used to obtain different color shades by using mixtures of various ratios/percentage. Color intensities can be altered by varying the total dye amount (1 mg to 400 mg).
- A mixture of methyl methacrylate (MMA), allyl methacrylate (AMA), and the crosslinker triethyleneglycol dimethacrylate (TEGDMA) is copolymerized in presence of a radical initiator (lauroyl peroxide, LP) can be performed by suspension polymerization. For example, 200 g freshly destilled MMA, 670 mg LP, 2.875 g TEGDMA, and 10 g AMA can be mixed until a clear solution is obtained. The aqueous phase composed of 23 g polyvinylalcohol (PVA; 26/88), 5 g disodium hydrogen phosphate, and 290 mg sodium dihydrogen phosphate can be dissolved in 1000 ml deionized water. Polymerization can be performed by stirring at 130 rpm (initial 250 rpm for 5 to 10 min) at 67° C. for 1 h, than 2 h at 70° C., and finally 80° C. for 2 h. Particle sizes in the range of 50 to 1000 μm can be obtained. Hydrolysis can be performed with 5 g of the particles (taken from sieve fraction 212 to 350 μm) in 1500 ml ethylene glycol containing 75 g potassium hydroxide under reflux for 2 h. Afterwards, the particles can be washed extensively with deionized water until pH7 results. The water can be substituted by physiological saline, and osmolarity measured at 290±50 mOsmol/kg. 20 ml hydrated particles (in physiological saline) can be colored by adding 150 mg Reactive Blue 4 and Reactive Blue 19, respectively. The first dyeing can be performed at ambient temperature, the latter reaction at 70° C.; after 14 h, the particles can be washed with physiological saline until the solution remains optically colorless.
- A mixture of methyl methacrylate (MMA), diallylurea (DAU) and the crosslinker triethyleneglycol dimethacrylate (TEGDMA) is copolymerized in presence of a radical initiator (lauroyl peroxide, LP) can be performed by suspension polymerization. For example, 100 g freshly distilled MMA, 330 mg LP, 1.43 g TEGDMA, and 1.0 g DAU can be mixed until a clear solution is obtained. The aqueous phase composed of 11.5 g polyvinylalcohol (PVA; 26/88), 2.5 g disodium hydrogen phosphate, and 145 mg sodium dihydrogen phosphate can be dissolved in 500 ml deionized water. Polymerization can be performed by stirring at 130 rpm (initial 250 rpm for 5 to 10 min) at 67° C. for 1 h, than 2 h at 70° C. and finally 80° C. for 2 h. Particle sizes in the range of 50 to 800 μm. Hydrolysis can be performed with 5 g of the particles in 1500 ml ethylene glycol containing 75 g potassium hydroxide under reflux for 2 h. Afterwards, the particles can be washed extensively with deionized water until pH of 7 results. The water can be substituted by physiological saline, and osmolarity measured at 290±50 mOsmol/kg. 20 ml hydrated particles (in physiological saline) can be colored by adding 150 mg Reactive Blue 4 and Reactive Blue 19, respectively. The first dyeing can be performed at ambient temperature, the latter reaction at 70° C.; after 16 h, the particles can be washed with physiological saline until the solution remains optically colorless.
- Reactive Dyes can bind to nucleophilic groups such as amines (primary amines preferred) or hydroxyl groups. To introduce amine groups to an acrylate-based hydrogels, 100 mg dry particles can be hydrated in 5 ml deionized water for 10 to 15 min. Afterwards, 100 mg 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 100 μm ethylene diamine (EDA) can be added and shaken gently for 2 h at ambient temperature. After extensive washing with potable water the beads can be dyed in 5 ml deionized water by adding 200 mg Reactive Blue 4 and Reactive Blue 19, respectively. The first mixture can be kept at room temperature and the latter reaction at 70° C., both over night. The dye solution can be removed and the particles can be washed with potable water and afterwards 3-4 times with 8-9 ml 0.9% NaClaq until the transport solution (TS) is almost colorless. Different color intensities can be prepared by varying EDA (20 μl to 200 μl), EDC (20 mg to 200 mg), and dye amount (10 mg to 40 0 mg); other colors can be also created by using Reactive Red 11, Reactive Red 180, Reactive Yellow 86, Reactive Yellow 15, Reactive Black 5, and Reactive Blue 21.
- To expand the color palette, a broader range of colors such as green, purple, and orange beads can be prepared as follows. As described above, various mixtures of dyes can be employed together to create the colors of interest, for example: (i) orange can be made by mixing red and yellow (ii) green can be made by mixing blue and yellow, and (iii) purple can be made by mixing blue and red. Dyes can be chosen within the same dye family (Remazol®: Reactive Yellow 15, Reactive Red 180, Reactive Black 5, Reactive Blue 21 and Reactive Blue 19; Procion®: Reactive Red 11, Reactive Yellow 86, Reactive Blue 4). Different color shades can be obtained by using mixtures of different ratios in the range of about 1:100 to about 100:1. Color intensities can be altered by varying EDA (20 μl to 200 μl), EDC (20 mg to 200 mg), and adjusting the total dye amount from about 10 mg to about 400 mg.
- To expand the color palette, a broader range of colors such as green, purple, pink, orange, grey, olive, smurf-blue, brown, ivory, black, burgundy, crimson, turquoise, orange beads can be prepared. Mixtures of at least two dyes can be utilized to create the described colors. Amino activated Reactive Yellow 86, Reactive Yellow 15, Reactive Blue 19, Reactive Red 180, Reactive Orange 78, Reactive Blue 163, Reactive Black 5, Reactive Blue 21, Reactive Blue 4, Reactive Blue 19, and Reactive Red 11 can be used. Different color shades can be obtained by using mixtures of all percentage ratios. Color intensities can be altered by varying EDC (20 mg to 500 mg), and adjusting the total dye amount from about 1 mg to about 400 mg.
- To expand the color palette, a broader range of colors such as green, purple, pink, orange, grey, olive, smurf-blue, brown, ivory, black, burgundy, crimson, turquoise, and orange beads can be prepared. After the first dyeing procedure, additional dyeing procedures can be applied utilizing another dye. Amino activated Reactive Yellow 86, Reactive Yellow 15, Reactive Blue 19, Reactive Red 180, Reactive Orange 78, Reactive Blue 163, Reactive Black 5, Reactive Blue 21, Reactive Blue 4, Reactive Blue 19, and Reactive Red 11 can be utilized, for example. Different color shades can be obtained altering dye amounts (0.1 mg to 20 mg) during the different dyeing procedures. Color intensities can be altered by varying EDC (20 mg to 500 mg), and adjusting the total dye amount from about 1 mg to 100 mg.
- Approximately 20 ml particles (900 μm) can be immersed in 80 ml 0.9% aqueous sodium chloride solution (physiological saline). First 2.6 ml aqueous iron(III) chloride (45%) can be added to this suspension, and then followed by 4 ml of 1 molar aqueous iron(II) sulfate. The suspension can be gently shaken for 10 to 15 min to reach diffusion equilibrium. 100 ml of 0.1 molar aqueous sodium hydroxide solution (containing 0.9% sodium chloride) can be added drop wise to allow iron hydroxide precipitation. The particles can be extensively washed with physiological saline. Rusty colored particles can be obtained. Different color intensities can be prepared by varying aqueous iron(III) chloride (45%) from 0.1 ml to 10 ml, 1 molar aqueous iron(II) sulfate from 0.15 ml to 15.5 ml, and aqueous sodium hydroxide from 0.1 molar to 1 molar and 4 ml to 400 ml, respectively.
- The particles can be prepared as described above, substituting 0.1 to 1 molar aqueous ammonia (NH3aq) in the place of sodium hydroxide. Different color intensities can be prepared by varying aqueous iron(III) chloride (45%) from 0.1 ml to 10 ml, 1 molar aqueous iron(II) sulfate from 0.15 ml to 15.5 ml, and aqueous ammonia from 0.1 molar to 1 molar and 4 ml to 400 ml, respectively.
- The particles can be prepared as described above, as follows. 3 ml hydrated particles (900 μm) can be immersed in 6 ml 0.9% aqueous sodium chloride solution (physiological saline). 2 ml of a saturated aqueous iron(II) sulfate solution (T=20° C.) can be added to the suspension and shaken gently for 10 to 15 min to reach diffusion equilibrium. 2 ml hydrogen peroxide (3%) can be added to the suspension for 5 to 6 min; afterwards the particles can be extensively washed with physiological saline, resulting in brownish colored particles. Different color intensities can be prepared by varying saturated aqueous iron(II) sulfate from 0.1 ml to 10 ml, hydrogen peroxide concentration from 0.1% to 5% utilizing an amount from 0.5 ml to 10 ml.
- The foregoing description, for purposes of explanation, used specific nomenclature to provide a thorough understanding of the invention. However, it will be apparent to one skilled in the art that the specific details are not required in order to practice the invention. The foregoing descriptions of specific embodiments of the present invention are presented for purpose of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed. Obviously many modifications and variations are possible in view of the above teachings. The embodiments are shown and described in order to best explain the principles of the invention and its practical applications, to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the following claims and their equivalent.
Claims (12)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/467,229 US20210299056A9 (en) | 2004-10-25 | 2009-05-15 | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
US14/720,428 US10973770B2 (en) | 2004-10-25 | 2015-05-22 | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US17/065,319 US11426355B2 (en) | 2004-10-25 | 2020-10-07 | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US17/814,896 US20220362161A1 (en) | 2004-10-25 | 2022-07-26 | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods ofpreparing and using the same |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62172904P | 2004-10-25 | 2004-10-25 | |
US68430705P | 2005-05-24 | 2005-05-24 | |
US11/257,535 US8318209B2 (en) | 2004-10-25 | 2005-10-25 | Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US96201507P | 2007-07-25 | 2007-07-25 | |
US11/924,674 US9107850B2 (en) | 2004-10-25 | 2007-10-26 | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US12/467,229 US20210299056A9 (en) | 2004-10-25 | 2009-05-15 | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/924,674 Continuation-In-Part US9107850B2 (en) | 2004-10-25 | 2007-10-26 | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/720,428 Division US10973770B2 (en) | 2004-10-25 | 2015-05-22 | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100028260A1 true US20100028260A1 (en) | 2010-02-04 |
US20210299056A9 US20210299056A9 (en) | 2021-09-30 |
Family
ID=41608582
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/467,229 Abandoned US20210299056A9 (en) | 2004-10-25 | 2009-05-15 | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
US14/720,428 Active 2027-10-13 US10973770B2 (en) | 2004-10-25 | 2015-05-22 | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/720,428 Active 2027-10-13 US10973770B2 (en) | 2004-10-25 | 2015-05-22 | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
Country Status (1)
Country | Link |
---|---|
US (2) | US20210299056A9 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408916B2 (en) | 2013-09-19 | 2016-08-09 | Microvention, Inc. | Polymer films |
US9546236B2 (en) | 2013-09-19 | 2017-01-17 | Terumo Corporation | Polymer particles |
US9688788B2 (en) | 2013-11-08 | 2017-06-27 | Terumo Corporation | Polymer particles |
US9907880B2 (en) | 2015-03-26 | 2018-03-06 | Microvention, Inc. | Particles |
US10201632B2 (en) | 2016-09-28 | 2019-02-12 | Terumo Corporation | Polymer particles |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11426355B2 (en) | 2004-10-25 | 2022-08-30 | Varian Medical Systems, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4774189A (en) * | 1984-12-24 | 1988-09-27 | Flow Cytometry Standards Corp. | Fluorescent calibration microbeads simulating stained cells |
US20020068089A1 (en) * | 1998-03-06 | 2002-06-06 | Biosphere Medical, Inc. | Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
US20030099683A1 (en) * | 2000-03-18 | 2003-05-29 | Michael Grunze | Polyphosphazene derivatives |
US20030157142A1 (en) * | 2000-08-11 | 2003-08-21 | Stefan Nagel | Implants with a phosphazene-containing coating |
US20030211165A1 (en) * | 2000-03-24 | 2003-11-13 | Jean-Marie Vogel | Microspheres for active embolization |
US20090011073A1 (en) * | 2007-07-04 | 2009-01-08 | Fanuc Ltd | Stationary platen of injection molding machine |
US20090025601A1 (en) * | 2007-07-27 | 2009-01-29 | Sundar Vasudevan | Polymerizable dye-monomer conjugates for encapsulating pigment particles |
US20090110730A1 (en) * | 2007-10-30 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same |
US20110150954A1 (en) * | 2003-03-14 | 2011-06-23 | Sol-Gel Technologies Ltd. | Agent-encapsulating micro-and nanoparticles, methods for preparation of same and products containing same |
Family Cites Families (296)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE420565B (en) | 1974-06-06 | 1981-10-19 | Pharmacia Ab | AID FOR INTRAVASCULAR ADMINISTRATION FOR USE IN CONNECTION WITH INTRAVASCULAR ADMINISTRATION OF A SOLUTION OR SUSPENSION OF A DIAGNOSTIC AGENT |
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US3949073A (en) | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
US4166800A (en) | 1977-08-25 | 1979-09-04 | Sandoz, Inc. | Processes for preparation of microspheres |
DE2905878A1 (en) | 1979-02-16 | 1980-08-28 | Merck Patent Gmbh | IMPLANTATION MATERIALS AND METHOD FOR THEIR PRODUCTION |
US4311736A (en) | 1979-03-19 | 1982-01-19 | The Kendall Company | Article having organo-phosphonitrile rubber coating bonded to natural or synthetic rubber and method of making |
US4341844A (en) | 1979-10-25 | 1982-07-27 | The Kendall Company | Article having organo-phosphonitrile rubber coating bonded to natural or synthetic rubber and method of making |
US4318947A (en) | 1979-12-26 | 1982-03-09 | The Kendall Company | Polymer coating and curing process for catheters |
FR2482112B1 (en) | 1980-05-09 | 1985-06-07 | Pharmindustrie | NOVEL HYDROPHILIC COPOLYMERS BASED ON N- (TRIS (HYDROXYMETHYL) METHYL) ACRYLAMIDE, PROCESSES FOR THEIR PREPARATION, AQUEOUS GELS OF SAID COPOLYMERS AND THEIR USE AS ION EXCHANGERS |
US4698373A (en) | 1981-01-21 | 1987-10-06 | Dentsply Research & Development Corp. | Stable one part dental compositions employing ipn technology |
JPS5879915A (en) | 1981-11-09 | 1983-05-13 | Nippon Soda Co Ltd | Preparation of rod-shaped drug |
US4424208A (en) | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4440750A (en) | 1982-02-12 | 1984-04-03 | Collagen Corporation | Osteogenic composition and method |
US4582640A (en) | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
US4424395A (en) | 1982-03-11 | 1984-01-03 | The Dow Chemical Company | Carbamates of biphenyls |
US4535485A (en) | 1982-03-12 | 1985-08-20 | Medical Biological Sciences, Inc. | Polymeric acrylic prothesis |
US4547390A (en) | 1982-03-12 | 1985-10-15 | Medical Biological Sciences, Inc. | Process of making implantable prosthesis material of modified polymeric acrylic (PMMA) beads coated with PHEMA and barium sulfate |
JPS58206759A (en) | 1982-05-28 | 1983-12-02 | テルモ株式会社 | Medical container |
US4451647A (en) | 1982-06-21 | 1984-05-29 | Research Corporation | Heparinized polyorganophosphazenes |
US4480642A (en) | 1982-07-26 | 1984-11-06 | Health Products Research, Inc. | Dilation device for the cervix |
SU1085993A1 (en) | 1983-01-24 | 1984-04-15 | Московский ордена Ленина и ордена Трудового Красного Знамени химико-технологический институт им.Д.И.Менделеева | Process for preparing hydrophylic polyorganophosphasenes |
JPS59164723A (en) | 1983-03-10 | 1984-09-17 | Koken:Kk | Substrate containing regenerated collagen fibril and its preparation |
CA1225585A (en) | 1983-06-30 | 1987-08-18 | Maria T. Litvinova | Composition for embolization of blood vessels |
JPS6038307A (en) | 1983-08-11 | 1985-02-27 | Nippon Daigaku | Composite material for plugging |
US4728345A (en) | 1983-12-28 | 1988-03-01 | Monsanto Company | Multicomponent gas separation membranes having polyphosphazene coatings |
US4837285A (en) | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
US4537916A (en) | 1984-06-25 | 1985-08-27 | The Dow Chemical Company | Structured latex particles which are film forming and a process for their preparation |
US4557764A (en) | 1984-09-05 | 1985-12-10 | Collagen Corporation | Process for preparing malleable collagen and the product thereof |
US4883699A (en) | 1984-09-21 | 1989-11-28 | Menlo Care, Inc. | Polymeric article having high tensile energy to break when hydrated |
US4911691A (en) | 1984-09-21 | 1990-03-27 | Menlo Care, Inc. | Assembly for adminstering IV solution |
US4595713A (en) | 1985-01-22 | 1986-06-17 | Hexcel Corporation | Medical putty for tissue augmentation |
DE3503584C1 (en) | 1985-02-02 | 1986-06-12 | Degussa Ag, 6000 Frankfurt | Process for the preparation of suspension polymers |
US4592755A (en) | 1985-06-11 | 1986-06-03 | Ethyl Corporation | Mammary implant |
US4851046A (en) | 1985-06-19 | 1989-07-25 | University Of Florida | Periodontal osseous defect repair |
JPH0678434B2 (en) | 1985-10-14 | 1994-10-05 | チッソ株式会社 | Spherical particulate polyphosphazene and method for producing the same |
US4728570A (en) | 1985-10-29 | 1988-03-01 | United States Surgical Corporation | Calcium-hydroxide-treated polymeric implant matrial |
US4798876A (en) | 1985-11-12 | 1989-01-17 | Tyndale Plains-Hunter Ltd. | Hydrophilic polyurethane composition |
JPS6322843A (en) | 1986-02-14 | 1988-01-30 | Teijin Ltd | Polyphosphazene molding and production thereof |
US4880622A (en) | 1986-05-20 | 1989-11-14 | Research Corporation Technologies, Inc. | Water-soluble phosphazene polymers having pharmacological applications |
US4803075A (en) | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US4849285A (en) | 1987-06-01 | 1989-07-18 | Bio Med Sciences, Inc. | Composite macrostructure of ceramic and organic biomaterials |
WO1988009664A1 (en) | 1987-06-10 | 1988-12-15 | Massachusetts Institute Of Technology | Polyphosphazene matrix erosion and diffusion release systems |
US4912141A (en) | 1987-07-28 | 1990-03-27 | Kronman Joseph H | Fibrous and cartilaginous tissue replacement |
US4902511A (en) | 1987-07-28 | 1990-02-20 | Kronman Joseph H | Fibrous and cartilaginous tissue replacement |
JPH01265970A (en) | 1988-04-19 | 1989-10-24 | Shiseido Co Ltd | Collagen water solution or water dispersion solution including hyaluronic acid |
US5634946A (en) | 1988-08-24 | 1997-06-03 | Focal, Inc. | Polymeric endoluminal paving process |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5306500A (en) | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
US5304595A (en) | 1988-11-21 | 1994-04-19 | Collagen Corporation | Collagen-polymer conjugates |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
DE3841401A1 (en) | 1988-12-08 | 1990-06-13 | Martin Lemperle | ALLOPLASTIC IMPLANT |
US5258028A (en) | 1988-12-12 | 1993-11-02 | Ersek Robert A | Textured micro implants |
US4975280A (en) | 1989-01-23 | 1990-12-04 | Ethyl Corporation | Bioerodable sustained release implants |
US5395620A (en) | 1989-01-31 | 1995-03-07 | Coletica | Biodegradable microcapsules having walls composed of crosslinked atelocollagen and polyholoside |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5007940A (en) | 1989-06-09 | 1991-04-16 | American Medical Systems, Inc. | Injectable polymeric bodies |
US5116387A (en) | 1989-06-09 | 1992-05-26 | American Medical Systems, Inc. | Preparation of injectable polymeric bodies |
US5158573A (en) | 1989-06-09 | 1992-10-27 | American Medical Systems, Inc. | Injectable polymeric bodies |
JPH0351200A (en) | 1989-07-20 | 1991-03-05 | Maruishi Kasei Kk | Palette with paint |
US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5246698A (en) | 1990-07-09 | 1993-09-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
DE4024371C2 (en) | 1990-08-01 | 1994-10-13 | Degussa | Process for the preparation of suspension polymers using phosphonic acids or their ammonium or alkali metal salts as dispersing aid additives |
US5487390A (en) | 1990-10-05 | 1996-01-30 | Massachusetts Institute Of Technology | Gas-filled polymeric microbubbles for ultrasound imaging |
US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
US5562099A (en) | 1990-10-05 | 1996-10-08 | Massachusetts Institute Of Technology | Polymeric microparticles containing agents for imaging |
US5342557A (en) | 1990-11-27 | 1994-08-30 | United States Surgical Corporation | Process for preparing polymer particles |
US6391343B1 (en) | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
AU652022B2 (en) | 1991-02-12 | 1994-08-11 | C.R. Bard Inc. | Injectable medical device |
JPH04337328A (en) | 1991-05-13 | 1992-11-25 | Shin Etsu Chem Co Ltd | Production of phosphazene polymer |
FR2676927B1 (en) | 1991-05-29 | 1995-06-23 | Ibf | MICROSPHERES FOR USE IN THERAPEUTIC VASCULAR OCCLUSIONS AND INJECTABLE SOLUTIONS CONTAINING THEM. |
CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
FR2679466B1 (en) | 1991-07-25 | 1994-04-15 | Ceramique Technique | FILTRATION MEMBRANE AND MANUFACTURING METHOD. |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
JP3356447B2 (en) | 1991-10-16 | 2002-12-16 | テルモ株式会社 | Vascular lesion embolic material composed of dried polymer gel |
DE4138513A1 (en) | 1991-11-23 | 1993-05-27 | Basf Ag | SOLID PHARMACEUTICAL RETARD FORM |
US6537574B1 (en) | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
US7968110B2 (en) | 1992-02-11 | 2011-06-28 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
US7060287B1 (en) | 1992-02-11 | 2006-06-13 | Bioform Inc. | Tissue augmentation material and method |
US5204382A (en) | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
DK0632820T3 (en) | 1992-02-28 | 2000-10-02 | Collagen Corp | Highly concentrated, homogenized collagen compositions |
DE69331096T2 (en) | 1992-02-28 | 2002-08-14 | Cohesion Tech Inc | INJECTABLE, CERAMIC COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
DE69332500T2 (en) | 1992-04-24 | 2004-01-29 | Chienna Bv | DEVICE FOR AVOIDING TISSUE ADHESIONS |
AU4926193A (en) | 1992-09-21 | 1994-04-12 | Vitaphore Corporation | Embolization plugs for blood vessels |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
DE784487T1 (en) | 1993-03-19 | 1999-11-04 | Q Med Ab Uppsala | A PREPARATION AND TISSUE PROPAGATION METHOD |
US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
ATE502664T1 (en) | 1993-07-19 | 2011-04-15 | Angiotech Pharm Inc | METHOD OF PRODUCTION OF A STENT WITH ANTI-ANGIOGENIC COMPOSITION |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US5397352A (en) | 1993-08-27 | 1995-03-14 | Burres; Steven | Method of recollagenation |
US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
US5681873A (en) | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
WO1995020362A1 (en) | 1994-01-26 | 1995-08-03 | Reiley Mark A | Improved inflatable device for use in surgical protocol relating to fixation of bone |
US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US6235061B1 (en) | 1994-04-04 | 2001-05-22 | The Penn State Research Foundation | Poly(organophosphazene) matrices for bone replacement |
US5464932A (en) | 1994-04-15 | 1995-11-07 | The Penn State Research Foundation | Photocrosslinkable polyphosphazenes and their use as microencapsulation materials |
GB9407812D0 (en) | 1994-04-20 | 1994-06-15 | Nycomed Salutar Inc | Compounds |
FR2721198B1 (en) | 1994-06-16 | 1996-10-31 | Caravel Jean Baudoin | Flexible implantable prosthesis, used in surgery for volume increase or soft tissue reconstruction, in particular breast prosthesis. |
ATE296140T1 (en) | 1994-06-27 | 2005-06-15 | Bard Peripheral Vascular Inc | RADIALLY EXPANDABLE POLYTETRAFLUORETHYLENE AND EXPANDABLE ENDOVASCULAR STENTS MOLDED THEREFROM |
US5855895A (en) | 1995-06-07 | 1999-01-05 | Virus Research Institute | Polyphosphazene polyelectrolyte immunoadjuvants |
US5451406A (en) | 1994-07-14 | 1995-09-19 | Advanced Uroscience, Inc. | Tissue injectable composition and method of use |
US5788979A (en) | 1994-07-22 | 1998-08-04 | Inflow Dynamics Inc. | Biodegradable coating with inhibitory properties for application to biocompatible materials |
DE4428056A1 (en) | 1994-07-29 | 1996-02-08 | Schering Ag | Use of microparticle preparations to eliminate dissolved, non-renal substances from the blood |
US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
US5548060A (en) | 1994-08-08 | 1996-08-20 | Penn State Research Foundation, Inc. | Sulfonation of polyphosphazenes |
AU706434B2 (en) | 1994-10-18 | 1999-06-17 | Ethicon Inc. | Injectable liquid copolymers for soft tissue repair and augmentation |
US5599852A (en) | 1994-10-18 | 1997-02-04 | Ethicon, Inc. | Injectable microdispersions for soft tissue repair and augmentation |
US6335383B1 (en) | 1994-10-18 | 2002-01-01 | Ethicon, Inc. | Microdispersions for coating surgical devices |
EP0713707A1 (en) | 1994-11-23 | 1996-05-29 | Collagen Corporation | In situ crosslinkable, injectable collagen composition for tissue augmention |
US6281015B1 (en) | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
CA2213403C (en) | 1995-02-22 | 2007-01-16 | Menlo Care, Inc. | Covered expanding mesh stent |
US6962979B1 (en) | 1995-03-14 | 2005-11-08 | Cohesion Technologies, Inc. | Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents |
US6337389B1 (en) | 1995-03-17 | 2002-01-08 | Bioscience Consultants, L.L.C. | Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof |
US5686113A (en) | 1995-03-21 | 1997-11-11 | Temple University Of The Commonwealth System Of Higher Education | Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses |
DE19613048C2 (en) | 1995-03-30 | 1997-12-18 | Michael Prof Dr Grunze | Artificial implants with antithrombogenic properties and processes for their production |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5914388A (en) | 1995-04-26 | 1999-06-22 | The Penn State Research Foundation | Synthesis polyphosphazenes with controlled molecular weight and polydisperity |
US6214331B1 (en) | 1995-06-06 | 2001-04-10 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
US6284284B1 (en) | 1995-06-06 | 2001-09-04 | Advanced Tissue Sciences, Inc. | Compositions and methods for production and use of an injectable naturally secreted extracellular matrix |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US5752974A (en) | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
US5955143A (en) | 1995-12-21 | 1999-09-21 | Drexel University | Hollow polymer microcapsules and method of producing the same |
FR2747682B1 (en) | 1996-04-17 | 1998-06-05 | Atochem Elf Sa | PROCESS FOR THE PREPARATION OF POLYMER POWDERS BY SUSPENSION POLYMERIZATION |
US5718159A (en) | 1996-04-30 | 1998-02-17 | Schneider (Usa) Inc. | Process for manufacturing three-dimensional braided covered stent |
US6190684B1 (en) | 1996-05-30 | 2001-02-20 | University Of Florida Research Foundation, Inc. | Injectable bio-active glass in a dextran suspension |
US5840290A (en) | 1996-05-30 | 1998-11-24 | University Of Florida Research Foundation | Injectable bio-active glass in a dextran suspension |
US6383500B1 (en) | 1996-06-27 | 2002-05-07 | Washington University | Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications |
US5807757A (en) | 1996-07-02 | 1998-09-15 | Virus Research Institute, Inc. | Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation |
US5792478A (en) | 1996-07-08 | 1998-08-11 | Advanced Uro Science | Tissue injectable composition and method of use |
US6666892B2 (en) | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6063061A (en) | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6254628B1 (en) | 1996-12-09 | 2001-07-03 | Micro Therapeutics, Inc. | Intracranial stent |
US6007573A (en) | 1996-09-18 | 1999-12-28 | Microtherapeutics, Inc. | Intracranial stent and method of use |
WO1998012274A1 (en) | 1996-09-23 | 1998-03-26 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
US5785642A (en) | 1996-10-18 | 1998-07-28 | Micro Therapeutics, Inc. | Methods for treating urinary incontinence in mammals |
US5707597A (en) | 1996-11-13 | 1998-01-13 | Virus Research Institute, Inc. | Polyhalophosphazene solutions stable against gelation |
BR9606075C1 (en) | 1996-12-19 | 2002-05-07 | Mateus Sommer Neto | Injectable composition for medical use. |
US5980972A (en) | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5814704A (en) | 1997-03-04 | 1998-09-29 | Virus Research Institute, Inc. | Recovery of polyphosphazene polyacids or acids salts thereof |
BR9808109A (en) | 1997-03-31 | 2000-03-08 | Neorx Corp | Therapeutic smooth muscle vascular cell inhibitor |
US6210715B1 (en) | 1997-04-01 | 2001-04-03 | Cap Biotechnology, Inc. | Calcium phosphate microcarriers and microspheres |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US20030153985A1 (en) | 1997-04-26 | 2003-08-14 | Lee Yong Chan | Medical implant |
TW586934B (en) | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
US6077916A (en) | 1997-06-04 | 2000-06-20 | The Penn State Research Foundation | Biodegradable mixtures of polyphoshazene and other polymers |
WO1998055100A1 (en) | 1997-06-05 | 1998-12-10 | Roland Bodmeier | Multiphase system |
WO1998056312A1 (en) | 1997-06-13 | 1998-12-17 | Scimed Life Systems, Inc. | Stents having multiple layers of biodegradable polymeric composition |
GB9712525D0 (en) | 1997-06-16 | 1997-08-20 | Nycomed Imaging As | Method |
US7192984B2 (en) | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
US20020197250A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
DE19735368A1 (en) | 1997-08-14 | 1999-02-18 | Univ Karlsruhe | New soluble polymeric thiosulphate(s) |
DE19744135C1 (en) | 1997-09-29 | 1999-03-25 | Schering Ag | Medical implants coated with epothilone |
DE19743373A1 (en) | 1997-09-30 | 1999-04-15 | Univ Heidelberg | · 3 ·· 2 · P-polyphosphazene |
FR2769223B1 (en) | 1997-10-03 | 2003-08-22 | Oreal | OXIDIZING COMPOSITION AND USES FOR DYING, FOR PERMANENT DEFORMATION OR FOR DECOLORATION OF KERATINIC FIBERS |
US6309420B1 (en) | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
US6485514B1 (en) | 1997-12-12 | 2002-11-26 | Supergen, Inc. | Local delivery of therapeutic agents |
US6423343B1 (en) | 1998-01-23 | 2002-07-23 | Usbiomaterials Corporation | Bioactive glass treatment of inflammation in skin conditions |
RU2215542C2 (en) | 1998-02-23 | 2003-11-10 | Массачусетс Инститьют Оф Текнолоджи | Biodecomposing polymers able recovery of form |
US6660301B1 (en) | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
US6207171B1 (en) | 1998-03-27 | 2001-03-27 | Avant Immunotherapeutics, Inc. | Polyphosphazene microspheres |
AU3552099A (en) | 1998-04-09 | 1999-11-01 | Charlotte-Mecklenburg Hospital Authority | Creation of three-dimensional tissues |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
DE69935716T2 (en) | 1998-05-05 | 2007-08-16 | Boston Scientific Ltd., St. Michael | STENT WITH SMOOTH ENDS |
US6254634B1 (en) | 1998-06-10 | 2001-07-03 | Surmodics, Inc. | Coating compositions |
US6933326B1 (en) | 1998-06-19 | 2005-08-23 | Lifecell Coporation | Particulate acellular tissue matrix |
BR9815931A (en) | 1998-06-30 | 2001-02-20 | Dow Chemical Co | Polymeric polyols, a process for their production, and polyurethane foam obtained |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US6514534B1 (en) | 1998-08-14 | 2003-02-04 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
DE19843254C2 (en) | 1998-09-10 | 2000-07-06 | Schering Ag | Use of polymer mixtures containing cyanoacrylate or methylene malonic ester for coating medical devices and implants, medical implants and processes for their production |
GB2345638A (en) | 1998-09-11 | 2000-07-19 | Tissue Science Lab Limited | Injectable collagen compositions |
US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
AU759016B2 (en) | 1998-10-05 | 2003-04-03 | Penn State Research Foundation, The | Compositions and methods for enhancing receptor-mediated cellular internalization |
FR2784580B1 (en) | 1998-10-16 | 2004-06-25 | Biosepra Inc | POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME |
US5997301A (en) | 1998-10-20 | 1999-12-07 | Linden; Lars Ake | Treatment of tooth surfaces and substances therefor |
US6261573B1 (en) | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
CA2353606A1 (en) | 1998-12-03 | 2000-06-08 | Boston Scientific Limited | Stent having drug crystals thereon |
US6251064B1 (en) | 1998-12-11 | 2001-06-26 | Enteric Medical Technologies, Inc. | Method for creating valve-like mechanism in natural body passageway |
US6238335B1 (en) | 1998-12-11 | 2001-05-29 | Enteric Medical Technologies, Inc. | Method for treating gastroesophageal reflux disease and apparatus for use therewith |
US20020016637A1 (en) | 1998-12-16 | 2002-02-07 | Mark A. Anton | Soft tissue filler |
IT1302534B1 (en) | 1998-12-21 | 2000-09-05 | Fidia Advanced Biopolymers Srl | INJECTABLE, BIOCOMPATIBLE AND BIODEGRADABLE COMPOSITIONS INCLUDING AT LEAST A DERIVATIVE OF HYALURONIC ACID, CHONDROGENIC CELLS, FOR |
EP1031354A3 (en) | 1999-01-19 | 2003-02-05 | Rohm And Haas Company | Polymeric MRI Contrast agents |
US6662805B2 (en) | 1999-03-24 | 2003-12-16 | The Johns Hopkins University | Method for composite cell-based implants |
WO2000056254A1 (en) | 1999-03-24 | 2000-09-28 | Parallax Medical, Inc. | Non-compliant system for delivery of implant material |
US6689823B1 (en) | 1999-03-31 | 2004-02-10 | The Brigham And Women's Hospital, Inc. | Nanocomposite surgical materials and method of producing them |
US20030007954A1 (en) | 1999-04-12 | 2003-01-09 | Gail K. Naughton | Methods for using a three-dimensional stromal tissue to promote angiogenesis |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
JP2001017121A (en) | 1999-07-05 | 2001-01-23 | Anpureenu Europe:Kk | Coated granule and its production |
JP3910314B2 (en) | 1999-07-23 | 2007-04-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Natural colorant |
US6423818B1 (en) | 1999-07-30 | 2002-07-23 | Takehisa Matsuda | Coumarin endcapped absorbable polymers |
US6503556B2 (en) | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US6713119B2 (en) | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US7025980B1 (en) | 1999-09-14 | 2006-04-11 | Tepha, Inc. | Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation |
US6277392B1 (en) | 1999-09-16 | 2001-08-21 | Carbon Medical Technologies, Inc. | Tissue injectable composition |
US6431174B1 (en) | 2000-08-10 | 2002-08-13 | Pi Medical, Inc. | Method and apparatus to treat conditions of the naso-pharyngeal area |
US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
KR100315630B1 (en) | 1999-11-17 | 2001-12-12 | 박호군 | Biodegradable and thermosensitive polyphosphazenes and their preparation method |
AU1609701A (en) | 1999-11-18 | 2001-05-30 | Sts Biopolymers, Inc. | Flexible sealed coil-like devices |
US7004977B2 (en) | 1999-11-24 | 2006-02-28 | A Enterprises, Inc. | Soft tissue substitute and method of soft tissue reformation |
US6355058B1 (en) | 1999-12-30 | 2002-03-12 | Advanced Cardiovascular Systems, Inc. | Stent with radiopaque coating consisting of particles in a binder |
AU4566001A (en) | 2000-03-13 | 2001-09-24 | Biocure Inc | Embolic compositions |
US7160931B2 (en) | 2000-03-15 | 2007-01-09 | Yu-Ling Cheng | Thermally reversible implant and filler |
US6436424B1 (en) | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
US7338657B2 (en) | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
US6263930B1 (en) | 2000-04-11 | 2001-07-24 | Scott A. Wiley | Stump grinder |
DE10019982A1 (en) | 2000-04-22 | 2001-10-25 | Univ Heidelberg | Use of antithrombogenic phosphazene polymer films or coverings on stents, catheters or other implants to reduce cell proliferation and hence to limit restenosis |
AU2001263760A1 (en) | 2000-04-11 | 2001-11-07 | Polyzenix Gmbh | Poly-tri-fluoro-ethoxypolyphosphazene coverings and films |
US6682760B2 (en) | 2000-04-18 | 2004-01-27 | Colbar R&D Ltd. | Cross-linked collagen matrices and methods for their preparation |
US6869445B1 (en) | 2000-05-04 | 2005-03-22 | Phillips Plastics Corp. | Packable ceramic beads for bone repair |
US20020005206A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US6528586B2 (en) | 2000-05-16 | 2003-03-04 | Gordon Mark Cohen | Compositions of elastomeric ethylene/(meth)acrylic (acid) ester copolymer and polylactone or polyether |
AU2001255438B2 (en) | 2000-05-16 | 2005-03-24 | Ortho-Mcneil Pharmaceutical, Inc. | Process for coating medical devices using super-critical carbon dioxide |
US6423332B1 (en) | 2000-05-26 | 2002-07-23 | Ethicon, Inc. | Method and composition for deforming soft tissues |
US7144414B2 (en) | 2000-06-27 | 2006-12-05 | Smith & Nephew, Inc. | Surgical procedures and instruments |
US6620185B1 (en) | 2000-06-27 | 2003-09-16 | Smith & Nephew, Inc. | Surgical procedures and instruments |
WO2002011696A2 (en) | 2000-08-08 | 2002-02-14 | Ev & M | Active tissue augmentation materials and method |
US6858634B2 (en) | 2000-09-15 | 2005-02-22 | Monsanto Technology Llc | Controlled release formulations and methods for their production and use |
AU2001286940A1 (en) | 2000-09-22 | 2002-04-02 | Kensey Nash Corporation | Drug delivering prostheses and methods of use |
ATE343969T1 (en) | 2000-09-29 | 2006-11-15 | Cordis Corp | COATED MEDICAL DEVICES |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US20040047892A1 (en) | 2000-11-15 | 2004-03-11 | Desrosiers Eric Andre | Filler composition for soft tissue augmentation and reconstructive surgery |
US6767637B2 (en) | 2000-12-13 | 2004-07-27 | Purdue Research Foundation | Microencapsulation using ultrasonic atomizers |
DE10100961B4 (en) | 2001-01-11 | 2005-08-04 | Polyzenix Gmbh | Body-compatible material and substrate coated with this material for the cultivation of cells and artificial organic implants constructed or grown from cells |
US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
US20070191964A1 (en) | 2001-04-04 | 2007-08-16 | Arthrocare Corporation | Enhanced visibility materials for implantation in hard tissue |
US20050209629A1 (en) | 2001-04-19 | 2005-09-22 | Kerr Sean H | Resorbable containment device and process for making and using same |
GB0115320D0 (en) | 2001-06-22 | 2001-08-15 | Univ Nottingham | Matrix |
BR0210722A (en) | 2001-06-29 | 2004-07-20 | Medgraft Microtech Inc | Biodegradable Injectable Implants and Related Methods of Production and Use |
US6967234B2 (en) | 2002-12-18 | 2005-11-22 | Ethicon, Inc. | Alkyd-lactone copolymers for medical applications |
ATE340551T1 (en) | 2001-08-17 | 2006-10-15 | Polyzenix Gmbh | DEVICE BASED ON NITINOL WITH POLYPHOSPHAZENE COVER |
US7195640B2 (en) | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
US20030065345A1 (en) | 2001-09-28 | 2003-04-03 | Kevin Weadock | Anastomosis devices and methods for treating anastomotic sites |
US20030065377A1 (en) | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US8133501B2 (en) | 2002-02-08 | 2012-03-13 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled drug delivery |
US6887270B2 (en) | 2002-02-08 | 2005-05-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US7094369B2 (en) | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
US7131997B2 (en) | 2002-03-29 | 2006-11-07 | Scimed Life Systems, Inc. | Tissue treatment |
US7053134B2 (en) | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
US6713646B2 (en) | 2002-04-12 | 2004-03-30 | Biosphere Medical | Degradable crosslinkers, and degradable crosslinked hydrogels comprising them |
US7271234B2 (en) | 2002-04-24 | 2007-09-18 | Rutgers, The State University Of New Jersey | Polyarylates for drug delivery and tissue engineering |
US7838699B2 (en) | 2002-05-08 | 2010-11-23 | Biosphere Medical | Embolization using degradable crosslinked hydrogels |
US20040028676A1 (en) | 2002-08-06 | 2004-02-12 | Klein Dean A. | Swallowing system tissue modifier |
US7026374B2 (en) | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
US7272144B2 (en) | 2002-06-26 | 2007-09-18 | Arris International, Inc. | Method and apparatus for queuing data flows |
AU2003281270B2 (en) * | 2002-07-02 | 2010-07-22 | Universitair Medisch Centrum Utrecht | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
DK1534352T3 (en) | 2002-07-05 | 2008-12-15 | Celonova Biosciences Germany G | Implant for transporting and delivering pharmacologically active agents as well as a method for preparing the same |
US20050136093A1 (en) | 2002-07-05 | 2005-06-23 | Polyzenix Gmbh | Implant for transport and release for pharmacologically active agents as well as a process for producing the same |
US6884905B2 (en) | 2002-07-23 | 2005-04-26 | Biosphere Medical | Degradable carbamate-containing bis(acryloyl) crosslinkers, and degradable crosslinked hydrogels comprising them |
US7588825B2 (en) | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
JP4337328B2 (en) | 2002-11-01 | 2009-09-30 | ソニー株式会社 | Encryption strength index calculation method, encryption strength evaluation processing device, and computer program |
US20040161470A1 (en) | 2002-11-22 | 2004-08-19 | Alexander Andrianov | Preparation of polyphosphazene microspheres |
WO2004060283A2 (en) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
US6872799B2 (en) | 2002-12-18 | 2005-03-29 | Ethicon, Inc. | Functionalized polymers for medical applications |
US6866860B2 (en) | 2002-12-19 | 2005-03-15 | Ethicon, Inc. | Cationic alkyd polyesters for medical applications |
JP2004250376A (en) | 2003-02-20 | 2004-09-09 | Lion Corp | Coloring matter for pharmaceutical composition, method for producing the same, the pharmaceutical composition and method for preventing its discoloration |
US20040186437A1 (en) | 2003-03-20 | 2004-09-23 | Frenette Claude E. | Content-coded medical syringe, syringe set and syringe content identification method |
KR20050120665A (en) | 2003-03-26 | 2005-12-22 | 폴리제닉스 게엠베하 | Coated dental implants |
US7655048B2 (en) | 2003-04-02 | 2010-02-02 | Furlow Jr Leonard T | Materials and methods for soft tissue augmentation |
US20050037047A1 (en) | 2003-08-11 | 2005-02-17 | Young-Ho Song | Medical devices comprising spray dried microparticles |
WO2005065079A2 (en) | 2003-11-10 | 2005-07-21 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
TW200603843A (en) | 2004-04-20 | 2006-02-01 | Technology Dev Company Ltd | Tissue enhancement implant and method |
US7217781B2 (en) | 2004-04-20 | 2007-05-15 | Parallel Solutions, Inc. | Polyphosphazenes including ionic or ionizable moieties and fluorine-containing moieties |
US20060246109A1 (en) | 2005-04-29 | 2006-11-02 | Hossainy Syed F | Concentration gradient profiles for control of agent release rates from polymer matrices |
EP1809349B1 (en) | 2004-07-05 | 2009-10-14 | Ziscoat N.V. | Biocompatible coating of medical devices comprising molecular sieves |
US20060008529A1 (en) | 2004-07-12 | 2006-01-12 | Meyerhoff Mark E | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers |
US7244270B2 (en) | 2004-09-16 | 2007-07-17 | Evera Medical | Systems and devices for soft tissue augmentation |
WO2006036269A2 (en) | 2004-09-24 | 2006-04-06 | Biosphere Medical, Inc. | Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof |
US20060147895A1 (en) | 2004-10-22 | 2006-07-06 | Cryofacets, Inc. | System, chamber, and method for fractionation, elutriation, and decontamination of fluids containing cellular components |
JP4885866B2 (en) | 2004-10-25 | 2012-02-29 | セロノヴァ バイオサイエンスィズ ジャーマニー ゲーエムベーハー | Fillable polyphosphazene-containing particles for therapeutic and / or diagnostic applications and methods for their preparation and use |
US9114162B2 (en) * | 2004-10-25 | 2015-08-25 | Celonova Biosciences, Inc. | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
US20070009612A1 (en) | 2004-12-16 | 2007-01-11 | Barefoot Robert R | Method for administering a composition to an animal |
US7308939B2 (en) | 2005-03-09 | 2007-12-18 | Halliburton Energy Services, Inc. | Methods of using polymer-coated particulates |
JP2005199723A (en) | 2005-03-10 | 2005-07-28 | Pilot Ink Co Ltd | Cap for ball-point pen |
CN104815331A (en) | 2005-05-09 | 2015-08-05 | 生物领域医疗公司 | Compositions and methods using microspheres and non-ionic contrast agents |
US8263109B2 (en) | 2005-05-09 | 2012-09-11 | Boston Scientific Scimed, Inc. | Injectable bulking compositions |
US20070003584A1 (en) | 2005-06-16 | 2007-01-04 | Russell Anderson | Liquid crystal polymer syringes and containers and methods of use for long term storage of filler materials |
WO2006138669A2 (en) | 2005-06-16 | 2006-12-28 | Artes Medical, Inc. | Life-like anatomic feature for testing injection of soft tissue fillers |
US20070100449A1 (en) | 2005-10-31 | 2007-05-03 | O'neil Michael | Injectable soft tissue fixation technique |
WO2007056316A2 (en) | 2005-11-04 | 2007-05-18 | University Of Virginia Patent Foundation | Injectable physiological temperature setting cement composites for spinal fusion and related method thereof |
US20070142786A1 (en) * | 2005-12-16 | 2007-06-21 | Lampropoulos Fred P | System with color-coded medical syringes and basins |
US8673019B2 (en) | 2006-04-13 | 2014-03-18 | Warsaw Orthopedic, Inc. | Use of anti-inflammatory compounds with allograft tissue implantation |
US20080058954A1 (en) | 2006-08-22 | 2008-03-06 | Hai Trieu | Methods of treating spinal injuries using injectable flowable compositions comprising organic materials |
-
2009
- 2009-05-15 US US12/467,229 patent/US20210299056A9/en not_active Abandoned
-
2015
- 2015-05-22 US US14/720,428 patent/US10973770B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4774189A (en) * | 1984-12-24 | 1988-09-27 | Flow Cytometry Standards Corp. | Fluorescent calibration microbeads simulating stained cells |
US20020068089A1 (en) * | 1998-03-06 | 2002-06-06 | Biosphere Medical, Inc. | Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
US20030099683A1 (en) * | 2000-03-18 | 2003-05-29 | Michael Grunze | Polyphosphazene derivatives |
US20030211165A1 (en) * | 2000-03-24 | 2003-11-13 | Jean-Marie Vogel | Microspheres for active embolization |
US20030157142A1 (en) * | 2000-08-11 | 2003-08-21 | Stefan Nagel | Implants with a phosphazene-containing coating |
US20110150954A1 (en) * | 2003-03-14 | 2011-06-23 | Sol-Gel Technologies Ltd. | Agent-encapsulating micro-and nanoparticles, methods for preparation of same and products containing same |
US20090011073A1 (en) * | 2007-07-04 | 2009-01-08 | Fanuc Ltd | Stationary platen of injection molding machine |
US20090025601A1 (en) * | 2007-07-27 | 2009-01-29 | Sundar Vasudevan | Polymerizable dye-monomer conjugates for encapsulating pigment particles |
US20090110730A1 (en) * | 2007-10-30 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11135167B2 (en) | 2013-09-19 | 2021-10-05 | Terumo Corporation | Polymer particles |
US11104772B2 (en) | 2013-09-19 | 2021-08-31 | Microvention, Inc. | Polymer films |
US11786630B2 (en) | 2013-09-19 | 2023-10-17 | Terumo Corporation | Polymer particles |
US9408916B2 (en) | 2013-09-19 | 2016-08-09 | Microvention, Inc. | Polymer films |
US9938367B2 (en) | 2013-09-19 | 2018-04-10 | Terumo Corporation | Polymer particles |
US9546236B2 (en) | 2013-09-19 | 2017-01-17 | Terumo Corporation | Polymer particles |
US10144793B2 (en) | 2013-09-19 | 2018-12-04 | Terumo Corporation | Polymer particles |
US10227463B2 (en) | 2013-09-19 | 2019-03-12 | Microvention, Inc. | Polymer films |
US10118980B1 (en) | 2013-11-08 | 2018-11-06 | Terumo Corporation | Polymer particles |
US9688788B2 (en) | 2013-11-08 | 2017-06-27 | Terumo Corporation | Polymer particles |
US10519264B2 (en) | 2013-11-08 | 2019-12-31 | Terumo Corporation | Polymer particles |
US11261274B2 (en) | 2013-11-08 | 2022-03-01 | Terumo Corporation | Polymer particles |
US10543295B2 (en) | 2015-03-26 | 2020-01-28 | Microvention, Inc. | Particles |
US10792390B2 (en) | 2015-03-26 | 2020-10-06 | Microvention, Inc. | Particles |
US11857694B2 (en) | 2015-03-26 | 2024-01-02 | Microvention, Inc. | Particles |
US10155064B2 (en) | 2015-03-26 | 2018-12-18 | Microvention, Inc. | Particles |
US9907880B2 (en) | 2015-03-26 | 2018-03-06 | Microvention, Inc. | Particles |
US11759545B2 (en) | 2016-09-28 | 2023-09-19 | Terumo Corporation | Polymer particles |
US10201632B2 (en) | 2016-09-28 | 2019-02-12 | Terumo Corporation | Polymer particles |
US11110198B2 (en) | 2016-09-28 | 2021-09-07 | Terumo Corporation | Polymer particles |
US11617814B2 (en) | 2016-09-28 | 2023-04-04 | Terumo Corporation | Methods of treatment comprising administering polymer particles configured for intravascular delivery of pharmaceutical agents |
US10632226B2 (en) | 2016-09-28 | 2020-04-28 | Terumo Corporation | Polymer particles |
US10729805B2 (en) | 2016-09-28 | 2020-08-04 | Terumo Corporation | Drug delivery polymer particles with hydrolytically degradable linkages |
US10328175B2 (en) | 2016-09-28 | 2019-06-25 | Terumo Corporation | Polymer particles |
Also Published As
Publication number | Publication date |
---|---|
US20150250736A1 (en) | 2015-09-10 |
US20210299056A9 (en) | 2021-09-30 |
US10973770B2 (en) | 2021-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100028260A1 (en) | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods | |
Paris et al. | Mesoporous silica nanoparticles engineered for ultrasound-induced uptake by cancer cells | |
Yang et al. | Pharmacokinetics and biodistribution of near-infrared fluorescence polymeric nanoparticles | |
KR101506557B1 (en) | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same | |
JP5848332B2 (en) | Functional cross-linked nanostructures for optical contrast and therapy tandems | |
BR112015008245B1 (en) | POLYMERIC TREATMENT COMPOSITIONS | |
US9687552B2 (en) | Association of poly(N-acryloylglycinamide) with at least one active principle | |
KR20110085932A (en) | Nanocarriers with enhanced skin permeability, cellular uptake and tumor targeting | |
EP2838577A1 (en) | Hydrophilic polymeric coatings for medical articles with visualization moiety | |
CN111205411B (en) | Blood vessel and tumor enhancement macromolecule magnetic resonance contrast agent and preparation method and application thereof | |
CN106693040A (en) | Preparation method of drug-loadable polyvinyl alcohol eluted microspheres | |
CN105164204A (en) | Compositions and methods for reducing oxidative damage | |
Lin et al. | Rapid in situ MRI traceable gel-forming dual-drug delivery for synergistic therapy of brain tumor | |
US20200030238A1 (en) | Microspheres containing therapeutic agents and related methods of use | |
US20090110730A1 (en) | Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same | |
ES2882098T3 (en) | Medical device that includes an anionic drug | |
CN110664753B (en) | Bone-targeting hypoxia-responsive nano micelle loaded with anticancer drug and preparation method thereof | |
Gallo et al. | Systematic overview of soft materials as a novel frontier for MRI contrast agents | |
US20100098637A1 (en) | Dye-loaded nanoparticle | |
Singh et al. | CuAAC ensembled 1, 2, 3-triazole linked nanogels for targeted drug delivery: A review | |
WO2009058147A1 (en) | Loadable polymeric particles for therapeutic use in erectile dysfunction | |
ES2455441A1 (en) | Hydrogel used as an injectable support for application in cell therapy and as a system for the controlled release of drugs | |
US20090110731A1 (en) | Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same | |
US20080226723A1 (en) | Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same | |
US20090110738A1 (en) | Loadable Polymeric Particles for Cosmetic and Reconstructive Tissue Augmentation Applications and Methods of Preparing and Using the Same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELONOVA BIOSCIENCES, INC., GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRITZ, ULF;FRITZ, OLAF;GORDY, THOMAS A.;AND OTHERS;SIGNING DATES FROM 20091002 TO 20091005;REEL/FRAME:023385/0982 Owner name: CELONOVA BIOSCIENCES, INC.,GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRITZ, ULF;FRITZ, OLAF;GORDY, THOMAS A.;AND OTHERS;SIGNING DATES FROM 20091002 TO 20091005;REEL/FRAME:023385/0982 |
|
AS | Assignment |
Owner name: CELONOVA BIOSCIENCES, INC., GEORGIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ADDITION OF THE INVENTOR, ALEXANDER KULLER PREVIOUSLY RECORDED ON REEL 023385 FRAME 0982. ASSIGNOR(S) HEREBY CONFIRMS THE ADDITION OF THE INVENTOR, ALEXANDER KULLER TO THE ASSIGNMENT RECORDATION;ASSIGNORS:FRITZ, ULF;FRITZ, OLAF;GORDY, THOMAS A.;AND OTHERS;SIGNING DATES FROM 20091002 TO 20091008;REEL/FRAME:023552/0588 Owner name: CELONOVA BIOSCIENCES, INC.,GEORGIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ADDITION OF THE INVENTOR, ALEXANDER KULLER PREVIOUSLY RECORDED ON REEL 023385 FRAME 0982. ASSIGNOR(S) HEREBY CONFIRMS THE ADDITION OF THE INVENTOR, ALEXANDER KULLER TO THE ASSIGNMENT RECORDATION;ASSIGNORS:FRITZ, ULF;FRITZ, OLAF;GORDY, THOMAS A.;AND OTHERS;SIGNING DATES FROM 20091002 TO 20091008;REEL/FRAME:023552/0588 |
|
AS | Assignment |
Owner name: BOSTON SCIENTIFIC LIMITED, BERMUDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CELONOVA BIOSCIENCES, INC.;REEL/FRAME:038054/0341 Effective date: 20151229 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: VARIAN MEDICAL SYSTEMS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOSTON SCIENTIFIC CORPORATION;REEL/FRAME:051511/0504 Effective date: 20190821 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |